

TDMS No. 20011 - 06

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

1-Bromopropane

CAS Number: 106-94-5

F1_M3

Date Report Requested: 10/01/2008

Time Report Requested: 09:42:38

First Dose M/F: 07/21/03 / 07/21/03

Lab: BNW

C Number: C20011
Lock Date: 06/15/2006
Cage Range: ALL
Date Range: ALL
Reasons For Removal: ALL
Removal Date Range: ALL
Treatment Groups: Include ALL
Study Gender: Both
TDMSE Version: 2.0.0

TDMS No. 20011 - 06

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

1-Bromopropane

CAS Number: 106-94-5

Date Report Requested: 10/01/2008

Time Report Requested: 09:42:38

First Dose M/F: 07/21/03 / 07/21/03

Lab: BNW

SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS IN THE ANALYSIS OF 1-Bromopropane

MALE MICE

Organ

Epididymis
Heart
Kidney
Larynx
Liver

Lung: Alveolus
Lung: Bronchiole

Nose
Nose: Olfactory Epithelium

Nose: Respiratory Epithelium

Spleen
Stomach, Glandular
Thymus: Medulla
Trachea

FEMALE MICE

Organ

Adrenal Cortex

Adrenal Medulla
Bone Marrow
Eye
Heart
Kidney

Morphology

Necrosis
Mineralization
Mineralization
Vacuolization Cytoplasmic
Angiectasis
Eosinophilic Focus
Fatty Change Focal
Mixed Cell Focus
Infiltration Cellular Histiocyte
Hyperplasia
Regeneration
Vacuolization Cytoplasmic
Polyp, Inflammatory
Atrophy
Metaplasia Respiratory
Hyperplasia
Vacuolization Cytoplasmic
Atrophy
Mineralization
Hyperplasia Lymphoid
Vacuolization Cytoplasmic

Morphology

Hyperplasia
Hypertrophy
Hyperplasia
Angiectasis
Cataract
Mineralization
Metaplasia Osseous

TDMS No. 20011 - 06

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

1-Bromopropane

CAS Number: 106-94-5

Date Report Requested: 10/01/2008

Time Report Requested: 09:42:38

First Dose M/F: 07/21/03 / 07/21/03

Lab: BNW

SUMMARY OF STATISTICALLY SIGNIFICANT ($P \leq .05$) RESULTS IN THE ANALYSIS OF 1-Bromopropane

Larynx	Nephropathy
Liver	Vacuolization Cytoplasmic
	Fatty Change Focal
Lung: Alveolus	Tension Lipidosis
Lung: Bronchiole	Infiltration Cellular Histiocyte
	Regeneration
Lymph Node: Iliac	Vacuolization Cytoplasmic
Nose: Olfactory Epithelium	Angiectasis
	Atrophy
Nose: Respiratory Epithelium	Metaplasia Respiratory
	Hyperplasia
Ovary	Vacuolization Cytoplasmic
Pancreas	Cyst
Skin	Atrophy
Thymus	Inflammation Chronic
Thymus: Medulla	Necrosis Lymphoid
Trachea	Hyperplasia Lymphoid
Urinary Bladder: Artery	Vacuolization Cytoplasmic
	Inflammation Chronic

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Adrenal Cortex
Hyperplasia**

LESION RATES

OVERALL (a)	16/49 (33%)	18/50 (36%)	14/49 (29%)	12/50 (24%)
POLY-3 RATE (b)	16/44.47	18/43.47	14/44.94	12/42.69
POLY-3 PERCENT (g)	36%	41.4%	31.2%	28.1%
TERMINAL (d)	12/37 (32%)	17/33 (52%)	12/32 (38%)	11/36 (31%)
FIRST INCIDENCE	539	696	628	385

STATISTICAL TESTS

POLY 3	P=0.168N	P=0.380	P=0.397N	P=0.288N
POLY 1.5	P=0.168N	P=0.412	P=0.393N	P=0.280N
POLY 6	P=0.169N	P=0.331	P=0.428N	P=0.299N
COCH-ARM / FISHERS	P=0.138N	P=0.445	P=0.413N	P=0.232N
MAX-ISO-POLY-3	P=0.249N	P=0.302	P=0.315N	P=0.222N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Adrenal Cortex
Hypertrophy**

LESION RATES

OVERALL (a)	23/49 (47%)	19/50 (38%)	22/49 (45%)	28/50 (56%)
POLY-3 RATE (b)	23/43.95	19/43.98	22/45.10	28/42.83
POLY-3 PERCENT (g)	52.3%	43.2%	48.8%	65.4%
TERMINAL (d)	21/37 (57%)	17/33 (52%)	18/32 (56%)	26/36 (72%)
FIRST INCIDENCE	539	631	628	417

STATISTICAL TESTS

POLY 3	P=0.071	P=0.256N	P=0.450N	P=0.148
POLY 1.5	P=0.075	P=0.246N	P=0.456N	P=0.158
POLY 6	P=0.069	P=0.278N	P=0.476N	P=0.142
COCH-ARM / FISHERS	P=0.118	P=0.243N	P=0.500N	P=0.242
MAX-ISO-POLY-3	P=0.077	P=0.192N	P=0.367N	P=0.106

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Adrenal Medulla
Hyperplasia**

LESION RATES

OVERALL (a)	1/50 (2%)	2/49 (4%)	1/49 (2%)	2/50 (4%)
POLY-3 RATE (b)	1/44.57	2/43.28	1/44.54	2/42.57
POLY-3 PERCENT (g)	2.2%	4.6%	2.3%	4.7%
TERMINAL (d)	0/37 (0%)	1/33 (3%)	1/32 (3%)	1/36 (3%)
FIRST INCIDENCE	610	684	729 (T)	470

STATISTICAL TESTS

POLY 3	P=0.430	P=0.490	P=0.760	P=0.484
POLY 1.5	P=0.430	P=0.492	P=0.760	P=0.484
POLY 6	P=0.430	P=0.483	P=0.756	P=0.484
COCH-ARM / FISHERS	P=0.446	P=0.492	P=0.747	P=0.500
MAX-ISO-POLY-3	P=0.437	P=0.273	P=0.499	P=0.271

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Blood Vessel: Aorta
Mineralization**

LESION RATES

OVERALL (a)	2/3 (67%)	0/1 (0%)	0/0 (0%)	0/0 (0%)
POLY-3 RATE (b)	2/3.00	0/0.96	0/0.00	0/0.00
POLY-3 PERCENT (g)	66.7%	0%	0%	0%
TERMINAL (d)	0/1 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)
FIRST INCIDENCE	328	---	---	---

STATISTICAL TESTS

POLY 3	(e)	P=0.512N	(e)	(e)
POLY 1.5	(e)	P=0.506N	(e)	(e)
POLY 6	(e)	P=0.524N	(e)	(e)
COCH-ARM / FISHERS	P=0.876N	P=0.500N	(e)	(e)
MAX-ISO-POLY-3	(e)	P=0.217N	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Bone Marrow
Angiectasis**

LESION RATES

OVERALL (a)	0/48 (0%)	0/48 (0%)	0/48 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/42.90	0/41.89	0/43.55	0/41.84
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/37 (0%)	0/33 (0%)	0/32 (0%)	0/36 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Bone
Hyperostosis**

LESION RATES

OVERALL (a)	0/50 (0%)	2/49 (4%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	0/44.16	2/43.14	0/45.30	1/41.84
POLY-3 PERCENT (g)	0%	4.6%	0%	2.4%
TERMINAL (d)	0/37 (0%)	1/33 (3%)	0/32 (0%)	1/36 (3%)
FIRST INCIDENCE	---	577	---	729 (T)

STATISTICAL TESTS

POLY 3	P=0.524	P=0.232	(e)	P=0.489
POLY 1.5	P=0.526	P=0.233	(e)	P=0.490
POLY 6	P=0.524	P=0.230	(e)	P=0.490
COCH-ARM / FISHERS	P=0.541	P=0.242	(e)	P=0.500
MAX-ISO-POLY-3	P=0.333	P=0.075	(e)	P=0.158

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Epididymis
Necrosis**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	0/44.16	0/43.34	0/45.30	2/43.84
POLY-3 PERCENT (g)	0%	0%	0%	4.6%
TERMINAL (d)	0/37 (0%)	0/33 (0%)	0/32 (0%)	0/36 (0%)
FIRST INCIDENCE	---	---	---	47

STATISTICAL TESTS

POLY 3	P=0.046*	(e)	(e)	P=0.235
POLY 1.5	P=0.045*	(e)	(e)	P=0.236
POLY 6	P=0.046*	(e)	(e)	P=0.236
COCH-ARM / FISHERS	P=0.046*	(e)	(e)	P=0.247
MAX-ISO-POLY-3	P=0.032*	(e)	(e)	P=0.076

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Eye
Cataract**

LESION RATES

OVERALL (a)	1/45 (2%)	1/47 (2%)	1/44 (2%)	0/47 (0%)
POLY-3 RATE (b)	1/40.93	1/42.20	1/40.82	0/40.89
POLY-3 PERCENT (g)	2.4%	2.4%	2.5%	0%
TERMINAL (d)	1/37 (3%)	0/32 (0%)	1/32 (3%)	0/36 (0%)
FIRST INCIDENCE	729 (T)	649	729 (T)	---

STATISTICAL TESTS

POLY 3	P=0.315N	P=0.754N	P=0.760	P=0.500N
POLY 1.5	P=0.314N	P=0.751N	P=0.760	P=0.498N
POLY 6	P=0.316N	P=0.760N	P=0.756	P=0.502N
COCH-ARM / FISHERS	P=0.306N	P=0.742N	P=0.747	P=0.489N
MAX-ISO-POLY-3	P=0.340N	P=0.490N	P=0.498	P=0.161N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Eye: Cornea
Inflammation Chronic**

LESION RATES

OVERALL (a)	2/45 (4%)	0/47 (0%)	1/44 (2%)	0/47 (0%)
POLY-3 RATE (b)	2/40.93	0/41.91	1/40.86	0/40.89
POLY-3 PERCENT (g)	4.9%	0%	2.5%	0%
TERMINAL (d)	2/37 (5%)	0/32 (0%)	0/32 (0%)	0/36 (0%)
FIRST INCIDENCE	729 (T)	---	718	---

STATISTICAL TESTS

POLY 3	P=0.186N	P=0.232N	P=0.501N	P=0.237N
POLY 1.5	P=0.187N	P=0.228N	P=0.501N	P=0.235N
POLY 6	P=0.183N	P=0.239N	P=0.506N	P=0.240N
COCH-ARM / FISHERS	P=0.185N	P=0.237N	P=0.509N	P=0.237N
MAX-ISO-POLY-3	P=0.081N	P=0.073N	P=0.282N	P=0.078N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

Eye: Cornea
Mineralization

LESION RATES

OVERALL (a)	0/45 (0%)	0/47 (0%)	0/44 (0%)	0/47 (0%)
POLY-3 RATE (b)	0/40.93	0/41.91	0/40.82	0/40.89
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/37 (0%)	0/32 (0%)	0/32 (0%)	0/36 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Gallbladder
Degeneration Hyaline**

LESION RATES

OVERALL (a)	2/40 (5%)	0/40 (0%)	0/34 (0%)	1/38 (3%)
POLY-3 RATE (b)	2/36.88	0/35.21	0/31.49	1/33.98
POLY-3 PERCENT (g)	5.4%	0%	0%	2.9%
TERMINAL (d)	2/34 (6%)	0/27 (0%)	0/25 (0%)	1/31 (3%)
FIRST INCIDENCE	729 (T)	---	---	729 (T)

STATISTICAL TESTS

POLY 3	P=0.471N	P=0.247N	P=0.272N	P=0.529N
POLY 1.5	P=0.474N	P=0.242N	P=0.272N	P=0.528N
POLY 6	P=0.467N	P=0.255N	P=0.276N	P=0.528N
COCH-ARM / FISHERS	P=0.480N	P=0.247N	P=0.289N	P=0.519N
MAX-ISO-POLY-3	P=0.170N	P=0.085N	P=0.100N	P=0.309N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Harderian Gland
Hyperplasia**

LESION RATES

OVERALL (a)	3/46 (7%)	4/49 (8%)	1/49 (2%)	4/48 (8%)
POLY-3 RATE (b)	3/41.38	4/42.73	1/44.54	4/42.15
POLY-3 PERCENT (g)	7.3%	9.4%	2.3%	9.5%
TERMINAL (d)	2/37 (5%)	3/33 (9%)	1/32 (3%)	3/36 (8%)
FIRST INCIDENCE	719	631	729 (T)	604

STATISTICAL TESTS

POLY 3	P=0.510	P=0.518	P=0.279N	P=0.510
POLY 1.5	P=0.509	P=0.527	P=0.277N	P=0.511
POLY 6	P=0.509	P=0.502	P=0.289N	P=0.508
COCH-ARM / FISHERS	P=0.515	P=0.536	P=0.285N	P=0.524
MAX-ISO-POLY-3	P=0.450	P=0.363	P=0.141N	P=0.356

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Heart
Cardiomyopathy**

LESION RATES

OVERALL (a)	12/50 (24%)	10/50 (20%)	14/50 (28%)	9/50 (18%)
POLY-3 RATE (b)	12/44.76	10/44.12	14/46.12	9/41.84
POLY-3 PERCENT (g)	26.8%	22.7%	30.4%	21.5%
TERMINAL (d)	9/37 (24%)	7/33 (21%)	11/32 (34%)	9/36 (25%)
FIRST INCIDENCE	610	568	617	729 (T)

STATISTICAL TESTS

POLY 3	P=0.399N	P=0.418N	P=0.443	P=0.373N
POLY 1.5	P=0.393N	P=0.409N	P=0.440	P=0.364N
POLY 6	P=0.403N	P=0.436N	P=0.425	P=0.381N
COCH-ARM / FISHERS	P=0.334N	P=0.405N	P=0.410	P=0.312N
MAX-ISO-POLY-3	P=0.471N	P=0.327N	P=0.355	P=0.290N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Heart
Mineralization**

LESION RATES

OVERALL (a)	2/50 (4%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	2/45.46	0/43.34	0/45.30	0/41.84
POLY-3 PERCENT (g)	4.4%	0%	0%	0%
TERMINAL (d)	0/37 (0%)	0/33 (0%)	0/32 (0%)	0/36 (0%)
FIRST INCIDENCE	328	---	---	---

STATISTICAL TESTS

POLY 3	P=0.107N	P=0.248N	P=0.238N	P=0.256N
POLY 1.5	P=0.109N	P=0.243N	P=0.236N	P=0.253N
POLY 6	P=0.106N	P=0.254N	P=0.244N	P=0.258N
COCH-ARM / FISHERS	P=0.115N	P=0.247N	P=0.247N	P=0.247N
MAX-ISO-POLY-3	P=0.048N*	P=0.086N	P=0.077N	P=0.094N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Heart
Thrombosis**

LESION RATES

OVERALL (a)	1/50 (2%)	2/50 (4%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	1/44.20	2/43.47	1/45.30	0/41.84
POLY-3 PERCENT (g)	2.3%	4.6%	2.2%	0%
TERMINAL (d)	0/37 (0%)	1/33 (3%)	1/32 (3%)	0/36 (0%)
FIRST INCIDENCE	719	696	729 (T)	---

STATISTICAL TESTS

POLY 3	P=0.260N	P=0.494	P=0.755N	P=0.511N
POLY 1.5	P=0.259N	P=0.498	P=0.755N	P=0.510N
POLY 6	P=0.260N	P=0.488	P=0.760N	P=0.511N
COCH-ARM / FISHERS	P=0.247N	P=0.500	P=0.753N	P=0.500N
MAX-ISO-POLY-3	P=0.248N	P=0.277	P=0.492N	P=0.172N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Islets, Pancreatic
Hyperplasia**

LESION RATES

OVERALL (a)	1/48 (2%)	0/50 (0%)	0/48 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/42.90	0/43.34	0/43.74	0/41.84
POLY-3 PERCENT (g)	2.3%	0%	0%	0%
TERMINAL (d)	1/37 (3%)	0/33 (0%)	0/32 (0%)	0/36 (0%)
FIRST INCIDENCE	729 (T)	---	---	---

STATISTICAL TESTS

POLY 3	P=0.291N	P=0.498N	P=0.496N	P=0.505N
POLY 1.5	P=0.294N	P=0.495N	P=0.496N	P=0.503N
POLY 6	P=0.290N	P=0.503N	P=0.500N	P=0.506N
COCH-ARM / FISHERS	P=0.302N	P=0.490N	P=0.500N	P=0.490N
MAX-ISO-POLY-3	P=0.136N	P=0.158N	P=0.158N	P=0.167N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Kidney
Infarct**

LESION RATES

OVERALL (a)	1/49 (2%)	2/50 (4%)	3/50 (6%)	1/49 (2%)
POLY-3 RATE (b)	1/44.17	2/44.10	3/45.45	1/41.72
POLY-3 PERCENT (g)	2.3%	4.5%	6.6%	2.4%
TERMINAL (d)	0/37 (0%)	0/33 (0%)	2/32 (6%)	1/36 (3%)
FIRST INCIDENCE	610	577	691	729 (T)

STATISTICAL TESTS

POLY 3	P=0.595	P=0.499	P=0.315	P=0.748
POLY 1.5	P=0.598	P=0.504	P=0.318	P=0.749
POLY 6	P=0.593	P=0.493	P=0.306	P=0.746
COCH-ARM / FISHERS	P=0.579N	P=0.508	P=0.316	P=0.753N
MAX-ISO-POLY-3	P=0.477	P=0.281	P=0.164	P=0.484

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Kidney
Inflammation**

LESION RATES

OVERALL (a)	1/49 (2%)	0/50 (0%)	2/50 (4%)	2/49 (4%)
POLY-3 RATE (b)	1/44.48	0/43.34	2/45.45	2/41.72
POLY-3 PERCENT (g)	2.3%	0%	4.4%	4.8%
TERMINAL (d)	0/37 (0%)	0/33 (0%)	1/32 (3%)	2/36 (6%)
FIRST INCIDENCE	477	---	691	729 (T)

STATISTICAL TESTS

POLY 3	P=0.230	P=0.505N	P=0.508	P=0.478
POLY 1.5	P=0.230	P=0.501N	P=0.510	P=0.481
POLY 6	P=0.232	P=0.511N	P=0.499	P=0.475
COCH-ARM / FISHERS	P=0.243	P=0.495N	P=0.508	P=0.500
MAX-ISO-POLY-3	P=0.264	P=0.166N	P=0.288	P=0.268

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Kidney
Metaplasia Osseous**

LESION RATES

OVERALL (a)	2/49 (4%)	1/50 (2%)	0/50 (0%)	0/49 (0%)
POLY-3 RATE (b)	2/43.76	1/43.34	0/45.30	0/41.72
POLY-3 PERCENT (g)	4.6%	2.3%	0%	0%
TERMINAL (d)	2/37 (5%)	1/33 (3%)	0/32 (0%)	0/36 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	---	---

STATISTICAL TESTS

POLY 3	P=0.099N	P=0.503N	P=0.229N	P=0.248N
POLY 1.5	P=0.100N	P=0.498N	P=0.229N	P=0.247N
POLY 6	P=0.099N	P=0.512N	P=0.234N	P=0.248N
COCH-ARM / FISHERS	P=0.100N	P=0.492N	P=0.242N	P=0.247N
MAX-ISO-POLY-3	P=0.089N	P=0.285N	P=0.075N	P=0.086N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Kidney
Mineralization**

LESION RATES

OVERALL (a)	2/49 (4%)	0/50 (0%)	0/50 (0%)	0/49 (0%)
POLY-3 RATE (b)	2/44.15	0/43.34	0/45.30	0/41.72
POLY-3 PERCENT (g)	4.5%	0%	0%	0%
TERMINAL (d)	1/37 (3%)	0/33 (0%)	0/32 (0%)	0/36 (0%)
FIRST INCIDENCE	617	---	---	---

STATISTICAL TESTS

POLY 3	P=0.107N	P=0.241N	P=0.231N	P=0.250N
POLY 1.5	P=0.109N	P=0.237N	P=0.230N	P=0.248N
POLY 6	P=0.106N	P=0.248N	P=0.238N	P=0.251N
COCH-ARM / FISHERS	P=0.114N	P=0.242N	P=0.242N	P=0.247N
MAX-ISO-POLY-3	P=0.042N*	P=0.081N	P=0.075N	P=0.088N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Kidney
Nephropathy**

LESION RATES

OVERALL (a)	44/49 (90%)	46/50 (92%)	47/50 (94%)	41/49 (84%)
POLY-3 RATE (b)	44/45.89	46/47.92	47/49.77	41/44.67
POLY-3 PERCENT (g)	95.9%	96%	94.4%	91.8%
TERMINAL (d)	37/37 (100%)	33/33 (100%)	31/32 (97%)	34/36 (94%)
FIRST INCIDENCE	544	424	537	417

STATISTICAL TESTS

POLY 3	P=0.199N	P=0.735	P=0.564N	P=0.330N
POLY 1.5	P=0.246N	P=0.638	P=0.652	P=0.366N
POLY 6	P=0.169N	P=0.801N	P=0.427N	P=0.321N
COCH-ARM / FISHERS	P=0.166N	P=0.487	P=0.346	P=0.276N
MAX-ISO-POLY-3	P=0.270N	P=0.487	P=0.361N	P=0.174N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Kidney: Renal Tubule
Hyperplasia**

LESION RATES

OVERALL (a)	2/49 (4%)	1/50 (2%)	2/50 (4%)	0/49 (0%)
POLY-3 RATE (b)	2/43.76	1/43.34	2/45.95	0/41.72
POLY-3 PERCENT (g)	4.6%	2.3%	4.4%	0%
TERMINAL (d)	2/37 (5%)	1/33 (3%)	0/32 (0%)	0/36 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	621	---

STATISTICAL TESTS

POLY 3	P=0.208N	P=0.503N	P=0.676N	P=0.248N
POLY 1.5	P=0.209N	P=0.498N	P=0.677N	P=0.247N
POLY 6	P=0.206N	P=0.512N	P=0.681N	P=0.248N
COCH-ARM / FISHERS	P=0.200N	P=0.492N	P=0.684N	P=0.247N
MAX-ISO-POLY-3	P=0.175N	P=0.285N	P=0.479N	P=0.086N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Larynx
Vacuolization Cytoplasmic**

LESION RATES

OVERALL (a)	0/48 (0%)	5/50 (10%)	10/48 (21%)	11/50 (22%)
POLY-3 RATE (b)	0/42.89	5/43.80	10/44.34	11/42.27
POLY-3 PERCENT (g)	0%	11.4%	22.6%	26%
TERMINAL (d)	0/37 (0%)	2/33 (6%)	7/32 (22%)	10/36 (28%)
FIRST INCIDENCE	---	661	604	604

STATISTICAL TESTS

POLY 3	P<0.001**	P=0.032*	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P=0.033*	P<0.001**	P<0.001**
POLY 6	P<0.001**	P=0.030*	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.031*	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P=0.010**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Liver
Angiectasis**

LESION RATES

OVERALL (a)	0/50 (0%)	3/50 (6%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/44.16	3/43.63	0/45.30	0/41.84
POLY-3 PERCENT (g)	0%	6.9%	0%	0%
TERMINAL (d)	0/37 (0%)	2/33 (6%)	0/32 (0%)	0/36 (0%)
FIRST INCIDENCE	---	649	---	---

STATISTICAL TESTS

POLY 3	P=0.320N	P=0.116	(e)	(e)
POLY 1.5	P=0.318N	P=0.118	(e)	(e)
POLY 6	P=0.323N	P=0.114	(e)	(e)
COCH-ARM / FISHERS	P=0.311N	P=0.121	(e)	(e)
MAX-ISO-POLY-3	P=0.185N	P=0.038*	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Liver
Basophilic Focus**

LESION RATES

OVERALL (a)	1/50 (2%)	2/50 (4%)	1/50 (2%)	3/50 (6%)
POLY-3 RATE (b)	1/44.16	2/43.34	1/45.38	3/41.95
POLY-3 PERCENT (g)	2.3%	4.6%	2.2%	7.2%
TERMINAL (d)	1/37 (3%)	2/33 (6%)	0/32 (0%)	2/36 (6%)
FIRST INCIDENCE	729 (T)	729 (T)	709	702

STATISTICAL TESTS

POLY 3	P=0.225	P=0.493	P=0.755N	P=0.287
POLY 1.5	P=0.225	P=0.497	P=0.755N	P=0.288
POLY 6	P=0.227	P=0.487	P=0.758N	P=0.288
COCH-ARM / FISHERS	P=0.237	P=0.500	P=0.753N	P=0.309
MAX-ISO-POLY-3	P=0.213	P=0.277	P=0.492N	P=0.147

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

Liver
Clear Cell Focus

LESION RATES

OVERALL (a)	9/50 (18%)	14/50 (28%)	16/50 (32%)	12/50 (24%)
POLY-3 RATE (b)	9/44.16	14/43.51	16/45.34	12/41.84
POLY-3 PERCENT (g)	20.4%	32.2%	35.3%	28.7%
TERMINAL (d)	9/37 (24%)	13/33 (39%)	15/32 (47%)	12/36 (33%)
FIRST INCIDENCE	729 (T)	684	718	729 (T)

STATISTICAL TESTS

POLY 3	P=0.272	P=0.154	P=0.088	P=0.259
POLY 1.5	P=0.276	P=0.162	P=0.089	P=0.264
POLY 6	P=0.274	P=0.141	P=0.077	P=0.259
COCH-ARM / FISHERS	P=0.340	P=0.171	P=0.083	P=0.312
MAX-ISO-POLY-3	P=0.194	P=0.104	P=0.058	P=0.191

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Liver
Eosinophilic Focus**

LESION RATES

OVERALL (a)	20/50 (40%)	16/50 (32%)	8/50 (16%)	9/50 (18%)
POLY-3 RATE (b)	20/44.16	16/43.89	8/45.59	9/41.84
POLY-3 PERCENT (g)	45.3%	36.5%	17.6%	21.5%
TERMINAL (d)	20/37 (54%)	14/33 (42%)	7/32 (22%)	9/36 (25%)
FIRST INCIDENCE	729 (T)	649	649	729 (T)

STATISTICAL TESTS

POLY 3	P=0.005N**	P=0.263N	P=0.003N**	P=0.015N*
POLY 1.5	P=0.005N**	P=0.261N	P=0.004N**	P=0.016N*
POLY 6	P=0.004N**	P=0.271N	P=0.003N**	P=0.014N*
COCH-ARM / FISHERS	P=0.005N**	P=0.266N	P=0.007N**	P=0.013N*
MAX-ISO-POLY-3	P=0.007N**	P=0.197N	P=0.002N**	P=0.010N**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

Liver
Fatty Change

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/44.16	0/43.34	0/45.30	0/41.84
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/37 (0%)	0/33 (0%)	0/32 (0%)	0/36 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

Liver
Fatty Change Focal

LESION RATES

OVERALL (a)	1/50 (2%)	3/50 (6%)	0/50 (0%)	5/50 (10%)
POLY-3 RATE (b)	1/44.16	3/43.34	0/45.30	5/42.15
POLY-3 PERCENT (g)	2.3%	6.9%	0%	11.9%
TERMINAL (d)	1/37 (3%)	3/33 (9%)	0/32 (0%)	4/36 (11%)
FIRST INCIDENCE	729 (T)	729 (T)	---	645

STATISTICAL TESTS

POLY 3	P=0.068	P=0.298	P=0.495N	P=0.090
POLY 1.5	P=0.068	P=0.302	P=0.495N	P=0.091
POLY 6	P=0.068	P=0.291	P=0.498N	P=0.092
COCH-ARM / FISHERS	P=0.075	P=0.309	P=0.500N	P=0.102
MAX-ISO-POLY-3	P=0.036*	P=0.151	P=0.158N	P=0.042*

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Liver
Mixed Cell Focus**

LESION RATES

OVERALL (a)	2/50 (4%)	7/50 (14%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	2/44.16	7/44.34	1/45.30	1/41.84
POLY-3 PERCENT (g)	4.5%	15.8%	2.2%	2.4%
TERMINAL (d)	2/37 (5%)	4/33 (12%)	1/32 (3%)	1/36 (3%)
FIRST INCIDENCE	729 (T)	540	729 (T)	729 (T)

STATISTICAL TESTS

POLY 3	P=0.143N	P=0.079	P=0.491N	P=0.519N
POLY 1.5	P=0.143N	P=0.080	P=0.492N	P=0.518N
POLY 6	P=0.144N	P=0.077	P=0.497N	P=0.518N
COCH-ARM / FISHERS	P=0.135N	P=0.080	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.110N	P=0.039*	P=0.275N	P=0.301N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

Liver
Necrosis

LESION RATES

OVERALL (a)	5/50 (10%)	4/50 (8%)	3/50 (6%)	9/50 (18%)
POLY-3 RATE (b)	5/45.77	4/44.20	3/46.11	9/46.80
POLY-3 PERCENT (g)	10.9%	9.1%	6.5%	19.2%
TERMINAL (d)	1/37 (3%)	1/33 (3%)	1/32 (3%)	1/36 (3%)
FIRST INCIDENCE	401	631	604	47

STATISTICAL TESTS

POLY 3	P=0.108	P=0.522N	P=0.352N	P=0.205
POLY 1.5	P=0.103	P=0.512N	P=0.351N	P=0.199
POLY 6	P=0.114	P=0.533N	P=0.363N	P=0.216
COCH-ARM / FISHERS	P=0.099	P=0.500N	P=0.357N	P=0.194
MAX-ISO-POLY-3	P=0.091	P=0.385N	P=0.229N	P=0.135

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Liver
Tension Lipidosis**

LESION RATES

OVERALL (a)	4/50 (8%)	3/50 (6%)	6/50 (12%)	2/50 (4%)
POLY-3 RATE (b)	4/44.16	3/43.34	6/45.59	2/41.84
POLY-3 PERCENT (g)	9.1%	6.9%	13.2%	4.8%
TERMINAL (d)	4/37 (11%)	3/33 (9%)	5/32 (16%)	2/36 (6%)
FIRST INCIDENCE	729 (T)	729 (T)	649	729 (T)

STATISTICAL TESTS

POLY 3	P=0.371N	P=0.510N	P=0.390	P=0.362N
POLY 1.5	P=0.372N	P=0.504N	P=0.387	P=0.361N
POLY 6	P=0.366N	P=0.521N	P=0.381	P=0.361N
COCH-ARM / FISHERS	P=0.341N	P=0.500N	P=0.370	P=0.339N
MAX-ISO-POLY-3	P=0.345N	P=0.357N	P=0.273	P=0.226N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Lung
Hemorrhage**

LESION RATES

OVERALL (a)	2/50 (4%)	2/50 (4%)	0/49 (0%)	1/49 (2%)
POLY-3 RATE (b)	2/44.16	2/43.34	0/44.50	1/41.01
POLY-3 PERCENT (g)	4.5%	4.6%	0%	2.4%
TERMINAL (d)	2/37 (5%)	2/33 (6%)	0/32 (0%)	1/36 (3%)
FIRST INCIDENCE	729 (T)	729 (T)	---	729 (T)

STATISTICAL TESTS

POLY 3	P=0.306N	P=0.687	P=0.235N	P=0.526N
POLY 1.5	P=0.306N	P=0.691	P=0.236N	P=0.525N
POLY 6	P=0.306N	P=0.680	P=0.239N	P=0.524N
COCH-ARM / FISHERS	P=0.303N	P=0.691N	P=0.253N	P=0.508N
MAX-ISO-POLY-3	P=0.298N	P=0.492	P=0.077N	P=0.307N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Lung
Inflammation Chronic**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	2/49 (4%)	0/49 (0%)
POLY-3 RATE (b)	0/44.16	0/43.34	2/44.50	0/41.01
POLY-3 PERCENT (g)	0%	0%	4.5%	0%
TERMINAL (d)	0/37 (0%)	0/33 (0%)	2/32 (6%)	0/36 (0%)
FIRST INCIDENCE	---	---	729 (T)	---

STATISTICAL TESTS

POLY 3	P=0.559	(e)	P=0.239	(e)
POLY 1.5	P=0.559	(e)	P=0.238	(e)
POLY 6	P=0.566	(e)	P=0.235	(e)
COCH-ARM / FISHERS	P=0.590	(e)	P=0.242	(e)
MAX-ISO-POLY-3	P=0.266	(e)	P=0.079	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Lung: Alveolar Epithelium
Hyperplasia**

LESION RATES

OVERALL (a)	2/50 (4%)	2/50 (4%)	1/49 (2%)	5/49 (10%)
POLY-3 RATE (b)	2/44.16	2/43.60	1/44.50	5/41.01
POLY-3 PERCENT (g)	4.5%	4.6%	2.3%	12.2%
TERMINAL (d)	2/37 (5%)	1/33 (3%)	1/32 (3%)	5/36 (14%)
FIRST INCIDENCE	729 (T)	660	729 (T)	729 (T)

STATISTICAL TESTS

POLY 3	P=0.100	P=0.689	P=0.497N	P=0.186
POLY 1.5	P=0.101	P=0.692	P=0.498N	P=0.188
POLY 6	P=0.101	P=0.684	P=0.503N	P=0.188
COCH-ARM / FISHERS	P=0.108	P=0.691N	P=0.508N	P=0.210
MAX-ISO-POLY-3	P=0.085	P=0.494	P=0.280N	P=0.106

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Lung: Alveolus
Infiltration Cellular Histiocyte**

LESION RATES

OVERALL (a)	0/50 (0%)	3/50 (6%)	1/49 (2%)	1/49 (2%)
POLY-3 RATE (b)	0/44.16	3/43.34	1/44.50	1/41.01
POLY-3 PERCENT (g)	0%	6.9%	2.3%	2.4%
TERMINAL (d)	0/37 (0%)	3/33 (9%)	1/32 (3%)	1/36 (3%)
FIRST INCIDENCE	---	729 (T)	729 (T)	729 (T)

STATISTICAL TESTS

POLY 3	P=0.558	P=0.115	P=0.502	P=0.485
POLY 1.5	P=0.559	P=0.117	P=0.501	P=0.486
POLY 6	P=0.559	P=0.111	P=0.498	P=0.486
COCH-ARM / FISHERS	P=0.583	P=0.121	P=0.495	P=0.495
MAX-ISO-POLY-3	P=0.245	P=0.038*	P=0.162	P=0.157

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Lung: Bronchiole
Hyperplasia**

LESION RATES

OVERALL (a)	0/50 (0%)	3/50 (6%)	0/49 (0%)	1/49 (2%)
POLY-3 RATE (b)	0/44.16	3/43.60	0/44.50	1/41.01
POLY-3 PERCENT (g)	0%	6.9%	0%	2.4%
TERMINAL (d)	0/37 (0%)	2/33 (6%)	0/32 (0%)	1/36 (3%)
FIRST INCIDENCE	---	660	---	729 (T)

STATISTICAL TESTS

POLY 3	P=0.609	P=0.116	(e)	P=0.485
POLY 1.5	P=0.611	P=0.118	(e)	P=0.486
POLY 6	P=0.609	P=0.113	(e)	P=0.486
COCH-ARM / FISHERS	P=0.627	P=0.121	(e)	P=0.495
MAX-ISO-POLY-3	P=0.289	P=0.038*	(e)	P=0.157

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Lung: Bronchiole
Regeneration**

LESION RATES

OVERALL (a)	1/50 (2%)	44/50 (88%)	38/49 (78%)	47/49 (96%)
POLY-3 RATE (b)	1/44.16	44/48.21	38/47.53	47/47.12
POLY-3 PERCENT (g)	2.3%	91.3%	80%	99.7%
TERMINAL (d)	1/37 (3%)	32/33 (97%)	28/32 (88%)	36/36 (100%)
FIRST INCIDENCE	729 (T)	425	537	47

STATISTICAL TESTS

POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Lung: Bronchiole
Vacuolization Cytoplasmic**

LESION RATES

OVERALL (a)	0/50 (0%)	18/50 (36%)	19/49 (39%)	17/49 (35%)
POLY-3 RATE (b)	0/44.16	18/44.48	19/45.77	17/44.45
POLY-3 PERCENT (g)	0%	40.5%	41.5%	38.3%
TERMINAL (d)	0/37 (0%)	13/33 (39%)	13/32 (41%)	11/36 (31%)
FIRST INCIDENCE	---	520	604	47

STATISTICAL TESTS

POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Lymph Node, Mesenteric
Angiectasis**

LESION RATES

OVERALL (a)	1/48 (2%)	0/46 (0%)	0/44 (0%)	0/48 (0%)
POLY-3 RATE (b)	1/42.90	0/41.16	0/39.89	0/41.72
POLY-3 PERCENT (g)	2.3%	0%	0%	0%
TERMINAL (d)	1/37 (3%)	0/33 (0%)	0/29 (0%)	0/36 (0%)
FIRST INCIDENCE	729 (T)	---	---	---

STATISTICAL TESTS

POLY 3	P=0.304N	P=0.508N	P=0.515N	P=0.506N
POLY 1.5	P=0.305N	P=0.507N	P=0.514N	P=0.505N
POLY 6	P=0.304N	P=0.511N	P=0.519N	P=0.506N
COCH-ARM / FISHERS	P=0.307N	P=0.511N	P=0.522N	P=0.500N
MAX-ISO-POLY-3	P=0.139N	P=0.166N	P=0.171N	P=0.165N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Lymph Node: Iliac
Angiectasis**

LESION RATES

OVERALL (a)	0/1 (0%)	0/1 (0%)	0/3 (0%)	0/0 (0%)
POLY-3 RATE (b)	0/1.00	0/0.92	0/2.92	0/0.00
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/1 (0%)	0/0 (0%)	0/2 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Mesentery: Fat
Necrosis**

LESION RATES

OVERALL (a)	7/9 (78%)	11/11 (100%)	5/6 (83%)	5/7 (71%)
POLY-3 RATE (b)	7/7.70	11/11.00	5/5.57	5/6.15
POLY-3 PERCENT (g)	90.9%	100%	89.8%	81.3%
TERMINAL (d)	6/6 (100%)	8/8 (100%)	4/4 (100%)	5/6 (83%)
FIRST INCIDENCE	586	631	649	729 (T)

STATISTICAL TESTS

POLY 3	P=0.279N	P=0.615	P=0.856N	P=0.615N
POLY 1.5	P=0.296N	P=0.381	P=0.806	P=0.620N
POLY 6	P=0.236N	P=0.928	P=0.963N	P=0.579N
COCH-ARM / FISHERS	P=0.334N	P=0.189	P=0.659	P=0.608N
MAX-ISO-POLY-3	P=0.226N	P=0.115	P=0.467N	P=0.298N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Nose
Inflammation**

LESION RATES

OVERALL (a)	2/50 (4%)	3/50 (6%)	2/50 (4%)	3/50 (6%)
POLY-3 RATE (b)	2/44.16	3/43.51	2/45.66	3/42.15
POLY-3 PERCENT (g)	4.5%	6.9%	4.4%	7.1%
TERMINAL (d)	2/37 (5%)	2/33 (6%)	1/32 (3%)	2/36 (6%)
FIRST INCIDENCE	729 (T)	684	628	645

STATISTICAL TESTS

POLY 3	P=0.437	P=0.493	P=0.682N	P=0.479
POLY 1.5	P=0.436	P=0.497	P=0.684N	P=0.479
POLY 6	P=0.442	P=0.486	P=0.687N	P=0.482
COCH-ARM / FISHERS	P=0.456	P=0.500	P=0.691N	P=0.500
MAX-ISO-POLY-3	P=0.493	P=0.319	P=0.486N	P=0.309

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Nose
Polyp, Inflammatory**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	3/50 (6%)
POLY-3 RATE (b)	0/44.16	0/43.34	0/45.30	3/41.84
POLY-3 PERCENT (g)	0%	0%	0%	7.2%
TERMINAL (d)	0/37 (0%)	0/33 (0%)	0/32 (0%)	3/36 (8%)
FIRST INCIDENCE	---	---	---	729 (T)

STATISTICAL TESTS

POLY 3	P=0.010**	(e)	(e)	P=0.109
POLY 1.5	P=0.010**	(e)	(e)	P=0.110
POLY 6	P=0.011*	(e)	(e)	P=0.109
COCH-ARM / FISHERS	P=0.012*	(e)	(e)	P=0.121
MAX-ISO-POLY-3	P=0.009**	(e)	(e)	P=0.038*

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Nose: Olfactory Epithelium
Atrophy**

LESION RATES

OVERALL (a)	2/50 (4%)	4/50 (8%)	7/50 (14%)	4/50 (8%)
POLY-3 RATE (b)	2/44.16	4/43.81	7/46.00	4/42.15
POLY-3 PERCENT (g)	4.5%	9.1%	15.2%	9.5%
TERMINAL (d)	2/37 (5%)	2/33 (6%)	4/32 (13%)	3/36 (8%)
FIRST INCIDENCE	729 (T)	649	628	645

STATISTICAL TESTS

POLY 3	P=0.255	P=0.333	P=0.088	P=0.315
POLY 1.5	P=0.255	P=0.336	P=0.087	P=0.316
POLY 6	P=0.261	P=0.328	P=0.086	P=0.319
COCH-ARM / FISHERS	P=0.289	P=0.339	P=0.080	P=0.339
MAX-ISO-POLY-3	P=0.180	P=0.198	P=0.047*	P=0.189

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Nose: Olfactory Epithelium
Metaplasia Respiratory**

LESION RATES

OVERALL (a)	0/50 (0%)	7/50 (14%)	6/50 (12%)	3/50 (6%)
POLY-3 RATE (b)	0/44.16	7/43.91	6/45.30	3/42.27
POLY-3 PERCENT (g)	0%	15.9%	13.3%	7.1%
TERMINAL (d)	0/37 (0%)	5/33 (15%)	6/32 (19%)	2/36 (6%)
FIRST INCIDENCE	---	649	729 (T)	604

STATISTICAL TESTS

POLY 3	P=0.322	P=0.007**	P=0.016*	P=0.111
POLY 1.5	P=0.321	P=0.007**	P=0.017*	P=0.111
POLY 6	P=0.328	P=0.007**	P=0.015*	P=0.112
COCH-ARM / FISHERS	P=0.362	P=0.006**	P=0.013*	P=0.121
MAX-ISO-POLY-3	P=0.041*	P=0.002**	P=0.006**	P=0.038*

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Nose: Respiratory Epithelium
Hyperplasia**

LESION RATES

OVERALL (a)	16/50 (32%)	29/50 (58%)	23/50 (46%)	26/50 (52%)
POLY-3 RATE (b)	16/46.49	29/47.02	23/46.88	26/44.49
POLY-3 PERCENT (g)	34.4%	61.7%	49.1%	58.4%
TERMINAL (d)	11/37 (30%)	19/33 (58%)	17/32 (53%)	20/36 (56%)
FIRST INCIDENCE	477	424	604	417

STATISTICAL TESTS

POLY 3	P=0.051	P=0.006**	P=0.107	P=0.016*
POLY 1.5	P=0.055	P=0.006**	P=0.113	P=0.017*
POLY 6	P=0.049*	P=0.005**	P=0.091	P=0.016*
COCH-ARM / FISHERS	P=0.098	P=0.008**	P=0.109	P=0.034*
MAX-ISO-POLY-3	P=0.017*	P=0.003**	P=0.074	P=0.010**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Nose: Respiratory Epithelium
Vacuolization Cytoplasmic**

LESION RATES

OVERALL (a)	0/50 (0%)	12/50 (24%)	19/50 (38%)	20/50 (40%)
POLY-3 RATE (b)	0/44.16	12/43.91	19/46.38	20/45.64
POLY-3 PERCENT (g)	0%	27.3%	41%	43.8%
TERMINAL (d)	0/37 (0%)	10/33 (30%)	13/32 (41%)	15/36 (42%)
FIRST INCIDENCE	---	649	604	47

STATISTICAL TESTS

POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Pancreas
Atrophy**

LESION RATES

OVERALL (a)	1/48 (2%)	0/50 (0%)	0/48 (0%)	1/50 (2%)
POLY-3 RATE (b)	1/42.90	0/43.34	0/43.74	1/41.84
POLY-3 PERCENT (g)	2.3%	0%	0%	2.4%
TERMINAL (d)	1/37 (3%)	0/33 (0%)	0/32 (0%)	1/36 (3%)
FIRST INCIDENCE	729 (T)	---	---	729 (T)

STATISTICAL TESTS

POLY 3	P=0.595	P=0.498N	P=0.496N	P=0.755
POLY 1.5	P=0.594	P=0.495N	P=0.496N	P=0.757
POLY 6	P=0.597	P=0.503N	P=0.500N	P=0.754
COCH-ARM / FISHERS	P=0.600	P=0.490N	P=0.500N	P=0.742N
MAX-ISO-POLY-3	P=0.405	P=0.158N	P=0.158N	P=0.492

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Pancreas
Basophilic Focus**

LESION RATES

OVERALL (a)	1/48 (2%)	0/50 (0%)	1/48 (2%)	0/50 (0%)
POLY-3 RATE (b)	1/42.90	0/43.34	1/44.01	0/41.84
POLY-3 PERCENT (g)	2.3%	0%	2.3%	0%
TERMINAL (d)	1/37 (3%)	0/33 (0%)	0/32 (0%)	0/36 (0%)
FIRST INCIDENCE	729 (T)	---	655	---

STATISTICAL TESTS

POLY 3	P=0.405N	P=0.498N	P=0.755N	P=0.505N
POLY 1.5	P=0.406N	P=0.495N	P=0.755N	P=0.503N
POLY 6	P=0.402N	P=0.503N	P=0.758N	P=0.506N
COCH-ARM / FISHERS	P=0.400N	P=0.490N	P=0.753N	P=0.490N
MAX-ISO-POLY-3	P=0.269N	P=0.158N	P=0.492N	P=0.167N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Pituitary Gland: Pars Distalis
Angiectasis**

LESION RATES

OVERALL (a)	0/46 (0%)	0/48 (0%)	0/46 (0%)	0/48 (0%)
POLY-3 RATE (b)	0/40.74	0/41.51	0/42.28	0/41.72
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/36 (0%)	0/32 (0%)	0/32 (0%)	0/36 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Pituitary Gland: Pars Distalis
Hyperplasia**

LESION RATES

OVERALL (a)	2/46 (4%)	2/48 (4%)	1/46 (2%)	1/48 (2%)
POLY-3 RATE (b)	2/40.74	2/41.51	1/42.28	1/41.72
POLY-3 PERCENT (g)	4.9%	4.8%	2.4%	2.4%
TERMINAL (d)	2/36 (6%)	2/32 (6%)	1/32 (3%)	1/36 (3%)
FIRST INCIDENCE	729 (T)	729 (T)	729 (T)	729 (T)

STATISTICAL TESTS

POLY 3	P=0.329N	P=0.688N	P=0.487N	P=0.492N
POLY 1.5	P=0.331N	P=0.682N	P=0.489N	P=0.492N
POLY 6	P=0.328N	P=0.692	P=0.491N	P=0.492N
COCH-ARM / FISHERS	P=0.328N	P=0.675N	P=0.500N	P=0.484N
MAX-ISO-POLY-3	P=0.437N	P=0.492N	P=0.273N	P=0.273N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Pituitary Gland: Pars Intermedia
Hyperplasia**

LESION RATES

OVERALL (a)	0/46 (0%)	0/48 (0%)	1/46 (2%)	0/48 (0%)
POLY-3 RATE (b)	0/40.74	0/41.51	1/42.55	0/41.72
POLY-3 PERCENT (g)	0%	0%	2.4%	0%
TERMINAL (d)	0/36 (0%)	0/32 (0%)	0/32 (0%)	0/36 (0%)
FIRST INCIDENCE	---	---	655	---

STATISTICAL TESTS

POLY 3	P=0.689	(e)	P=0.509	(e)
POLY 1.5	P=0.688	(e)	P=0.507	(e)
POLY 6	P=0.691	(e)	P=0.508	(e)
COCH-ARM / FISHERS	P=0.698	(e)	P=0.500	(e)
MAX-ISO-POLY-3	P=0.395	(e)	P=0.169	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Prostate
Inflammation**

LESION RATES

OVERALL (a)	2/49 (4%)	0/50 (0%)	2/48 (4%)	2/50 (4%)
POLY-3 RATE (b)	2/45.38	0/43.34	2/43.89	2/42.72
POLY-3 PERCENT (g)	4.4%	0%	4.6%	4.7%
TERMINAL (d)	0/37 (0%)	0/33 (0%)	1/32 (3%)	1/36 (3%)
FIRST INCIDENCE	328	---	677	360

STATISTICAL TESTS

POLY 3	P=0.431	P=0.248N	P=0.682	P=0.672
POLY 1.5	P=0.431	P=0.242N	P=0.685	P=0.677
POLY 6	P=0.435	P=0.255N	P=0.674	P=0.669
COCH-ARM / FISHERS	P=0.449	P=0.242N	P=0.684	P=0.684N
MAX-ISO-POLY-3	P=0.440	P=0.087N	P=0.486	P=0.475

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Skin
Inflammation Chronic**

LESION RATES

OVERALL (a)	5/50 (10%)	5/50 (10%)	3/50 (6%)	8/50 (16%)
POLY-3 RATE (b)	5/44.33	5/44.14	3/45.60	8/43.68
POLY-3 PERCENT (g)	11.3%	11.3%	6.6%	18.3%
TERMINAL (d)	4/37 (11%)	2/33 (6%)	1/32 (3%)	5/36 (14%)
FIRST INCIDENCE	684	631	677	360

STATISTICAL TESTS

POLY 3	P=0.201	P=0.628	P=0.341N	P=0.265
POLY 1.5	P=0.198	P=0.630	P=0.343N	P=0.261
POLY 6	P=0.204	P=0.623	P=0.349N	P=0.269
COCH-ARM / FISHERS	P=0.206	P=0.630N	P=0.357N	P=0.277
MAX-ISO-POLY-3	P=0.171	P=0.496	P=0.222N	P=0.179

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

Spleen Atrophy

LESION RATES

OVERALL (a)	7/48 (15%)	8/50 (16%)	2/49 (4%)	3/50 (6%)
POLY-3 RATE (b)	7/45.26	8/44.75	2/44.49	3/43.41
POLY-3 PERCENT (g)	15.5%	17.9%	4.5%	6.9%
TERMINAL (d)	2/37 (5%)	3/33 (9%)	1/32 (3%)	0/36 (0%)
FIRST INCIDENCE	477	520	718	468

STATISTICAL TESTS

POLY 3	P=0.060N	P=0.491	P=0.082N	P=0.174N
POLY 1.5	P=0.057N	P=0.511	P=0.077N	P=0.167N
POLY 6	P=0.064N	P=0.463	P=0.095N	P=0.183N
COCH-ARM / FISHERS	P=0.050N*	P=0.535	P=0.075N	P=0.142N
MAX-ISO-POLY-3	P=0.085N	P=0.381	P=0.042N*	P=0.108N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Spleen
Congestion**

LESION RATES

OVERALL (a)	4/48 (8%)	4/50 (8%)	1/49 (2%)	3/50 (6%)
POLY-3 RATE (b)	4/42.95	4/45.88	1/44.80	3/44.53
POLY-3 PERCENT (g)	9.3%	8.7%	2.2%	6.7%
TERMINAL (d)	3/37 (8%)	0/33 (0%)	0/32 (0%)	0/36 (0%)
FIRST INCIDENCE	718	424	631	47

STATISTICAL TESTS

POLY 3	P=0.332N	P=0.607N	P=0.166N	P=0.480N
POLY 1.5	P=0.333N	P=0.608N	P=0.166N	P=0.482N
POLY 6	P=0.331N	P=0.612N	P=0.171N	P=0.479N
COCH-ARM / FISHERS	P=0.329N	P=0.619N	P=0.175N	P=0.477N
MAX-ISO-POLY-3	P=0.302N	P=0.461N	P=0.079N	P=0.330N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Spleen
Hematopoietic Cell Proliferation**

LESION RATES

OVERALL (a)	20/48 (42%)	19/50 (38%)	14/49 (29%)	16/50 (32%)
POLY-3 RATE (b)	20/47.11	19/46.32	14/46.55	16/45.16
POLY-3 PERCENT (g)	42.5%	41%	30.1%	35.4%
TERMINAL (d)	11/37 (30%)	10/33 (30%)	7/32 (22%)	9/36 (25%)
FIRST INCIDENCE	328	520	537	385

STATISTICAL TESTS

POLY 3	P=0.220N	P=0.527N	P=0.150N	P=0.317N
POLY 1.5	P=0.212N	P=0.495N	P=0.139N	P=0.300N
POLY 6	P=0.227N	P=0.557N	P=0.173N	P=0.328N
COCH-ARM / FISHERS	P=0.159N	P=0.435N	P=0.127N	P=0.217N
MAX-ISO-POLY-3	P=0.280N	P=0.444N	P=0.107N	P=0.252N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Spleen
Hyperplasia**

LESION RATES

OVERALL (a)	0/48 (0%)	0/50 (0%)	0/49 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/42.90	0/43.34	0/44.45	0/41.84
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/37 (0%)	0/33 (0%)	0/32 (0%)	0/36 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Spleen
Hyperplasia Lymphoid**

LESION RATES

OVERALL (a)	5/48 (10%)	2/50 (4%)	5/49 (10%)	2/50 (4%)
POLY-3 RATE (b)	5/42.90	2/43.51	5/44.45	2/41.84
POLY-3 PERCENT (g)	11.7%	4.6%	11.3%	4.8%
TERMINAL (d)	5/37 (14%)	1/33 (3%)	5/32 (16%)	2/36 (6%)
FIRST INCIDENCE	729 (T)	684	729 (T)	729 (T)

STATISTICAL TESTS

POLY 3	P=0.266N	P=0.210N	P=0.608N	P=0.226N
POLY 1.5	P=0.265N	P=0.205N	P=0.606N	P=0.222N
POLY 6	P=0.264N	P=0.219N	P=0.624N	P=0.228N
COCH-ARM / FISHERS	P=0.242N	P=0.201N	P=0.617N	P=0.201N
MAX-ISO-POLY-3	P=0.210N	P=0.115N	P=0.476N	P=0.131N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Spleen
Necrosis Lymphoid**

LESION RATES

OVERALL (a)	1/48 (2%)	0/50 (0%)	1/49 (2%)	2/50 (4%)
POLY-3 RATE (b)	1/42.95	0/43.34	1/44.83	2/43.22
POLY-3 PERCENT (g)	2.3%	0%	2.2%	4.6%
TERMINAL (d)	0/37 (0%)	0/33 (0%)	0/32 (0%)	0/36 (0%)
FIRST INCIDENCE	718	---	621	360

STATISTICAL TESTS

POLY 3	P=0.252	P=0.498N	P=0.751N	P=0.502
POLY 1.5	P=0.249	P=0.495N	P=0.751N	P=0.502
POLY 6	P=0.256	P=0.504N	P=0.755N	P=0.503
COCH-ARM / FISHERS	P=0.255	P=0.490N	P=0.747N	P=0.515
MAX-ISO-POLY-3	P=0.233	P=0.159N	P=0.487N	P=0.283

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Spleen
Pigmentation Hemosiderin**

LESION RATES

OVERALL (a)	0/48 (0%)	0/50 (0%)	0/49 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/42.90	0/43.34	0/44.45	0/41.84
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/37 (0%)	0/33 (0%)	0/32 (0%)	0/36 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Stomach, Forestomach
Hyperplasia**

LESION RATES

OVERALL (a)	5/47 (11%)	7/50 (14%)	5/48 (10%)	3/50 (6%)
POLY-3 RATE (b)	5/42.36	7/44.14	5/43.91	3/41.84
POLY-3 PERCENT (g)	11.8%	15.9%	11.4%	7.2%
TERMINAL (d)	3/36 (8%)	4/33 (12%)	2/32 (6%)	3/36 (8%)
FIRST INCIDENCE	610	577	709	729 (T)

STATISTICAL TESTS

POLY 3	P=0.226N	P=0.408	P=0.608N	P=0.363N
POLY 1.5	P=0.221N	P=0.417	P=0.606N	P=0.356N
POLY 6	P=0.231N	P=0.393	P=0.622N	P=0.369N
COCH-ARM / FISHERS	P=0.191N	P=0.424	P=0.616N	P=0.323N
MAX-ISO-POLY-3	P=0.285N	P=0.295	P=0.475N	P=0.241N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Stomach, Forestomach
Inflammation**

LESION RATES

OVERALL (a)	2/47 (4%)	2/50 (4%)	1/48 (2%)	0/50 (0%)
POLY-3 RATE (b)	2/41.90	2/43.38	1/43.74	0/41.84
POLY-3 PERCENT (g)	4.8%	4.6%	2.3%	0%
TERMINAL (d)	2/36 (6%)	1/33 (3%)	1/32 (3%)	0/36 (0%)
FIRST INCIDENCE	729 (T)	719	729 (T)	---

STATISTICAL TESTS

POLY 3	P=0.126N	P=0.682N	P=0.485N	P=0.237N
POLY 1.5	P=0.125N	P=0.676N	P=0.485N	P=0.236N
POLY 6	P=0.126N	P=0.691N	P=0.491N	P=0.238N
COCH-ARM / FISHERS	P=0.118N	P=0.668N	P=0.492N	P=0.232N
MAX-ISO-POLY-3	P=0.164N	P=0.485N	P=0.271N	P=0.079N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Stomach, Forestomach
Ulcer**

LESION RATES

OVERALL (a)	2/47 (4%)	4/50 (8%)	3/48 (6%)	2/50 (4%)
POLY-3 RATE (b)	2/42.36	4/44.69	3/44.26	2/43.84
POLY-3 PERCENT (g)	4.7%	9%	6.8%	4.6%
TERMINAL (d)	0/36 (0%)	1/33 (3%)	0/32 (0%)	0/36 (0%)
FIRST INCIDENCE	610	540	604	47

STATISTICAL TESTS

POLY 3	P=0.470N	P=0.362	P=0.520	P=0.682N
POLY 1.5	P=0.465N	P=0.365	P=0.520	P=0.678N
POLY 6	P=0.475N	P=0.355	P=0.512	P=0.685N
COCH-ARM / FISHERS	P=0.457N	P=0.369	P=0.510	P=0.668N
MAX-ISO-POLY-3	P=0.524N	P=0.223	P=0.344	P=0.485N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Stomach, Glandular
Mineralization**

LESION RATES

OVERALL (a)	2/47 (4%)	0/49 (0%)	0/47 (0%)	0/49 (0%)
POLY-3 RATE (b)	2/43.44	0/42.59	0/42.89	0/41.01
POLY-3 PERCENT (g)	4.6%	0%	0%	0%
TERMINAL (d)	0/37 (0%)	0/33 (0%)	0/32 (0%)	0/36 (0%)
FIRST INCIDENCE	328	---	---	---

STATISTICAL TESTS

POLY 3	P=0.103N	P=0.241N	P=0.240N	P=0.250N
POLY 1.5	P=0.106N	P=0.236N	P=0.238N	P=0.246N
POLY 6	P=0.102N	P=0.249N	P=0.246N	P=0.253N
COCH-ARM / FISHERS	P=0.113N	P=0.237N	P=0.247N	P=0.237N
MAX-ISO-POLY-3	P=0.045N*	P=0.082N	P=0.079N	P=0.091N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Testes
Atrophy**

LESION RATES

OVERALL (a)	1/50 (2%)	1/50 (2%)	1/50 (2%)	3/50 (6%)
POLY-3 RATE (b)	1/44.16	1/43.38	1/45.30	3/43.84
POLY-3 PERCENT (g)	2.3%	2.3%	2.2%	6.8%
TERMINAL (d)	1/37 (3%)	0/33 (0%)	1/32 (3%)	1/36 (3%)
FIRST INCIDENCE	729 (T)	719	729 (T)	47

STATISTICAL TESTS

POLY 3	P=0.164	P=0.757	P=0.755N	P=0.302
POLY 1.5	P=0.164	P=0.759	P=0.755N	P=0.303
POLY 6	P=0.166	P=0.753	P=0.759N	P=0.304
COCH-ARM / FISHERS	P=0.163	P=0.753N	P=0.753N	P=0.309
MAX-ISO-POLY-3	P=0.191	P=0.494	P=0.492N	P=0.153

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Thymus
Atrophy**

LESION RATES

OVERALL (a)	13/38 (34%)	12/35 (34%)	19/37 (51%)	12/32 (38%)
POLY-3 RATE (b)	13/36.12	12/31.24	19/35.67	12/30.33
POLY-3 PERCENT (g)	36%	38.4%	53.3%	39.6%
TERMINAL (d)	8/29 (28%)	8/25 (32%)	13/28 (46%)	4/22 (18%)
FIRST INCIDENCE	401	577	628	47

STATISTICAL TESTS

POLY 3	P=0.359	P=0.519	P=0.106	P=0.482
POLY 1.5	P=0.344	P=0.545	P=0.105	P=0.477
POLY 6	P=0.387	P=0.499	P=0.106	P=0.499
COCH-ARM / FISHERS	P=0.338	P=0.594	P=0.102	P=0.485
MAX-ISO-POLY-3	P=0.308	P=0.421	P=0.068	P=0.386

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Thymus
Cyst**

LESION RATES

OVERALL (a)	5/38 (13%)	1/35 (3%)	7/37 (19%)	4/32 (13%)
POLY-3 RATE (b)	5/34.16	1/30.45	7/35.22	4/26.65
POLY-3 PERCENT (g)	14.6%	3.3%	19.9%	15%
TERMINAL (d)	4/29 (14%)	0/25 (0%)	4/28 (14%)	3/22 (14%)
FIRST INCIDENCE	719	577	628	645

STATISTICAL TESTS

POLY 3	P=0.344	P=0.126N	P=0.399	P=0.625
POLY 1.5	P=0.350	P=0.123N	P=0.385	P=0.633
POLY 6	P=0.343	P=0.129N	P=0.408	P=0.620
COCH-ARM / FISHERS	P=0.386	P=0.119N	P=0.358	P=0.611N
MAX-ISO-POLY-3	P=0.304	P=0.064N	P=0.288	P=0.484

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Thymus
Necrosis Lymphoid**

LESION RATES

OVERALL (a)	1/38 (3%)	0/35 (0%)	1/37 (3%)	3/32 (9%)
POLY-3 RATE (b)	1/34.84	0/29.95	1/34.85	3/27.77
POLY-3 PERCENT (g)	2.9%	0%	2.9%	10.8%
TERMINAL (d)	0/29 (0%)	0/25 (0%)	0/28 (0%)	0/22 (0%)
FIRST INCIDENCE	477	---	621	417

STATISTICAL TESTS

POLY 3	P=0.071	P=0.530N	P=0.761N	P=0.226
POLY 1.5	P=0.070	P=0.525N	P=0.759	P=0.229
POLY 6	P=0.072	P=0.536N	P=0.761	P=0.225
COCH-ARM / FISHERS	P=0.072	P=0.521N	P=0.747	P=0.245
MAX-ISO-POLY-3	P=0.061	P=0.190N	P=0.499N	P=0.117

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Thymus: Medulla
Hyperplasia Lymphoid**

LESION RATES

OVERALL (a)	16/38 (42%)	9/35 (26%)	14/37 (38%)	6/32 (19%)
POLY-3 RATE (b)	16/34.12	9/29.95	14/35.41	6/27.58
POLY-3 PERCENT (g)	46.9%	30.1%	39.5%	21.8%
TERMINAL (d)	16/29 (55%)	9/25 (36%)	9/28 (32%)	4/22 (18%)
FIRST INCIDENCE	729 (T)	729 (T)	621	468

STATISTICAL TESTS

POLY 3	P=0.048N*	P=0.127N	P=0.353N	P=0.033N*
POLY 1.5	P=0.054N	P=0.119N	P=0.385N	P=0.035N*
POLY 6	P=0.042N*	P=0.140N	P=0.324N	P=0.031N*
COCH-ARM / FISHERS	P=0.052N	P=0.110N	P=0.444N	P=0.032N*
MAX-ISO-POLY-3	P=0.039N*	P=0.090N	P=0.273N	P=0.024N*

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Tooth
Dysplasia**

LESION RATES

OVERALL (a)	7/8 (88%)	8/8 (100%)	9/9 (100%)	11/11 (100%)
POLY-3 RATE (b)	7/8.00	8/8.00	9/9.00	11/11.00
POLY-3 PERCENT (g)	87.5%	100%	100%	100%
TERMINAL (d)	6/7 (86%)	6/6 (100%)	7/7 (100%)	11/11 (100%)
FIRST INCIDENCE	691	649	628	729 (T)

STATISTICAL TESTS

POLY 3	P=0.266	P=0.500	P=0.476	P=0.436
POLY 1.5	P=0.266	P=0.500	P=0.476	P=0.436
POLY 6	P=0.266	P=0.500	P=0.476	P=0.436
COCH-ARM / FISHERS	P=0.265	P=0.500	P=0.471	P=0.421
MAX-ISO-POLY-3	P=0.102	P=0.159	P=0.150	P=0.135

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Trachea
Vacuolization Cytoplasmic**

LESION RATES

OVERALL (a)	0/49 (0%)	15/50 (30%)	24/47 (51%)	24/50 (48%)
POLY-3 RATE (b)	0/43.74	15/43.97	24/44.57	24/47.43
POLY-3 PERCENT (g)	0%	34.1%	53.9%	50.6%
TERMINAL (d)	0/37 (0%)	11/33 (33%)	16/32 (50%)	15/36 (42%)
FIRST INCIDENCE	---	660	604	47

STATISTICAL TESTS

POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Urinary Bladder: Artery
Inflammation Chronic**

LESION RATES

OVERALL (a)	0/47 (0%)	0/50 (0%)	0/47 (0%)	0/48 (0%)
POLY-3 RATE (b)	0/42.30	0/43.34	0/42.89	0/40.12
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/37 (0%)	0/33 (0%)	0/32 (0%)	0/36 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Adrenal Cortex
Hyperplasia**

LESION RATES

OVERALL (a)	3/50 (6%)	10/50 (20%)	4/50 (8%)	6/50 (12%)
POLY-3 RATE (b)	3/45.01	10/47.86	4/44.98	6/47.17
POLY-3 PERCENT (g)	6.7%	20.9%	8.9%	12.7%
TERMINAL (d)	2/36 (6%)	8/40 (20%)	4/37 (11%)	6/41 (15%)
FIRST INCIDENCE	607	547	731 (T)	731 (T)

STATISTICAL TESTS

POLY 3	P=0.490	P=0.045*	P=0.500	P=0.266
POLY 1.5	P=0.474	P=0.041*	P=0.498	P=0.256
POLY 6	P=0.513	P=0.051	P=0.503	P=0.281
COCH-ARM / FISHERS	P=0.455	P=0.036*	P=0.500	P=0.243
MAX-ISO-POLY-3	P=0.222	P=0.026*	P=0.347	P=0.171

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Adrenal Cortex
Hypertrophy**

LESION RATES

OVERALL (a)	4/50 (8%)	3/50 (6%)	1/50 (2%)	9/50 (18%)
POLY-3 RATE (b)	4/44.58	3/46.91	1/44.98	9/47.54
POLY-3 PERCENT (g)	9%	6.4%	2.2%	18.9%
TERMINAL (d)	4/36 (11%)	3/40 (8%)	1/37 (3%)	7/41 (17%)
FIRST INCIDENCE	731 (T)	731 (T)	731 (T)	663

STATISTICAL TESTS

POLY 3	P=0.040*	P=0.472N	P=0.176N	P=0.141
POLY 1.5	P=0.039*	P=0.484N	P=0.178N	P=0.130
POLY 6	P=0.043*	P=0.456N	P=0.171N	P=0.160
COCH-ARM / FISHERS	P=0.039*	P=0.500N	P=0.181N	P=0.117
MAX-ISO-POLY-3	P=0.025*	P=0.327N	P=0.082N	P=0.091

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Adrenal Medulla
Hyperplasia**

LESION RATES

OVERALL (a)	0/50 (0%)	5/50 (10%)	1/49 (2%)	4/50 (8%)
POLY-3 RATE (b)	0/44.58	5/47.28	1/44.05	4/47.45
POLY-3 PERCENT (g)	0%	10.6%	2.3%	8.4%
TERMINAL (d)	0/36 (0%)	4/40 (10%)	1/37 (3%)	3/41 (7%)
FIRST INCIDENCE	---	625	731 (T)	655

STATISTICAL TESTS

POLY 3	P=0.182	P=0.036*	P=0.498	P=0.069
POLY 1.5	P=0.171	P=0.034*	P=0.496	P=0.065
POLY 6	P=0.198	P=0.039*	P=0.500	P=0.075
COCH-ARM / FISHERS	P=0.162	P=0.028*	P=0.495	P=0.059
MAX-ISO-POLY-3	P=0.064	P=0.014*	P=0.157	P=0.026*

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Blood Vessel: Aorta
Mineralization**

LESION RATES

OVERALL (a)	0/0 (0%)	0/1 (0%)	0/1 (0%)	0/0 (0%)
POLY-3 RATE (b)	0/0.00	0/1.00	0/1.00	0/0.00
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/0 (0%)	0/1 (0%)	0/1 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Bone Marrow
Angiectasis**

LESION RATES

OVERALL (a)	2/50 (4%)	0/50 (0%)	0/49 (0%)	0/50 (0%)
POLY-3 RATE (b)	2/44.58	0/46.91	0/44.05	0/47.17
POLY-3 PERCENT (g)	4.5%	0%	0%	0%
TERMINAL (d)	2/36 (6%)	0/40 (0%)	0/37 (0%)	0/41 (0%)
FIRST INCIDENCE	731 (T)	---	---	---

STATISTICAL TESTS

POLY 3	P=0.120N	P=0.226N	P=0.240N	P=0.225N
POLY 1.5	P=0.118N	P=0.231N	P=0.241N	P=0.230N
POLY 6	P=0.123N	P=0.220N	P=0.237N	P=0.217N
COCH-ARM / FISHERS	P=0.116N	P=0.247N	P=0.253N	P=0.247N
MAX-ISO-POLY-3	P=0.033N*	P=0.076N	P=0.077N	P=0.076N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Bone
Hyperostosis**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/44.58	0/46.91	0/44.98	0/47.17
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/36 (0%)	0/40 (0%)	0/37 (0%)	0/41 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Eye
Cataract**

LESION RATES

OVERALL (a)	3/47 (6%)	1/49 (2%)	0/45 (0%)	2/50 (4%)
POLY-3 RATE (b)	3/42.88	1/46.13	0/41.26	2/47.18
POLY-3 PERCENT (g)	7%	2.2%	0%	4.2%
TERMINAL (d)	2/36 (6%)	1/40 (3%)	0/37 (0%)	1/41 (2%)
FIRST INCIDENCE	649	731 (T)	---	730

STATISTICAL TESTS

POLY 3	P=0.430N	P=0.279N	P=0.125N	P=0.457N
POLY 1.5	P=0.430N	P=0.284N	P=0.126N	P=0.463N
POLY 6	P=0.430N	P=0.274N	P=0.123N	P=0.448N
COCH-ARM / FISHERS	P=0.429N	P=0.293N	P=0.129N	P=0.470N
MAX-ISO-POLY-3	P=0.180N	P=0.143N	P=0.042N*	P=0.292N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

Eye: Cornea
Inflammation Chronic

LESION RATES

OVERALL (a)	1/47 (2%)	0/49 (0%)	2/45 (4%)	1/50 (2%)
POLY-3 RATE (b)	1/42.88	0/46.13	2/41.26	1/47.18
POLY-3 PERCENT (g)	2.3%	0%	4.9%	2.1%
TERMINAL (d)	0/36 (0%)	0/40 (0%)	2/37 (5%)	0/41 (0%)
FIRST INCIDENCE	649	---	731 (T)	730

STATISTICAL TESTS

POLY 3	P=0.522	P=0.485N	P=0.487	P=0.739N
POLY 1.5	P=0.518	P=0.488N	P=0.485	P=0.742N
POLY 6	P=0.527	P=0.482N	P=0.491	P=0.735N
COCH-ARM / FISHERS	P=0.513	P=0.490N	P=0.484	P=0.737N
MAX-ISO-POLY-3	P=0.392	P=0.156N	P=0.271	P=0.473N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Eye: Cornea
Mineralization**

LESION RATES

OVERALL (a)	1/47 (2%)	0/49 (0%)	2/45 (4%)	1/50 (2%)
POLY-3 RATE (b)	1/42.58	0/46.13	2/41.26	1/47.17
POLY-3 PERCENT (g)	2.4%	0%	4.9%	2.1%
TERMINAL (d)	1/36 (3%)	0/40 (0%)	2/37 (5%)	1/41 (2%)
FIRST INCIDENCE	731 (T)	---	731 (T)	731 (T)

STATISTICAL TESTS

POLY 3	P=0.524	P=0.484N	P=0.489	P=0.738N
POLY 1.5	P=0.519	P=0.487N	P=0.486	P=0.742N
POLY 6	P=0.530	P=0.480N	P=0.495	P=0.732N
COCH-ARM / FISHERS	P=0.513	P=0.490N	P=0.484	P=0.737N
MAX-ISO-POLY-3	P=0.395	P=0.156N	P=0.272	P=0.471N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Gallbladder
Degeneration Hyaline**

LESION RATES

OVERALL (a)	0/43 (0%)	0/36 (0%)	0/36 (0%)	0/44 (0%)
POLY-3 RATE (b)	0/39.17	0/33.16	0/33.38	0/41.28
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/33 (0%)	0/28 (0%)	0/30 (0%)	0/36 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Harderian Gland
Hyperplasia**

LESION RATES

OVERALL (a)	3/49 (6%)	1/49 (2%)	2/48 (4%)	6/50 (12%)
POLY-3 RATE (b)	3/44.27	1/46.13	2/43.56	6/47.17
POLY-3 PERCENT (g)	6.8%	2.2%	4.6%	12.7%
TERMINAL (d)	2/36 (6%)	1/40 (3%)	2/37 (5%)	6/41 (15%)
FIRST INCIDENCE	708	731 (T)	731 (T)	731 (T)

STATISTICAL TESTS

POLY 3	P=0.086	P=0.291N	P=0.507N	P=0.274
POLY 1.5	P=0.085	P=0.297N	P=0.510N	P=0.265
POLY 6	P=0.088	P=0.282N	P=0.502N	P=0.289
COCH-ARM / FISHERS	P=0.084	P=0.309N	P=0.510N	P=0.254
MAX-ISO-POLY-3	P=0.093	P=0.148N	P=0.330N	P=0.178

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Heart
Cardiomyopathy**

LESION RATES

OVERALL (a)	6/50 (12%)	12/50 (24%)	8/50 (16%)	8/50 (16%)
POLY-3 RATE (b)	6/44.58	12/47.76	8/45.46	8/47.43
POLY-3 PERCENT (g)	13.5%	25.1%	17.6%	16.9%
TERMINAL (d)	6/36 (17%)	9/40 (23%)	7/37 (19%)	7/41 (17%)
FIRST INCIDENCE	731 (T)	625	589	663

STATISTICAL TESTS

POLY 3	P=0.525N	P=0.124	P=0.401	P=0.435
POLY 1.5	P=0.548N	P=0.111	P=0.393	P=0.413
POLY 6	P=0.491N	P=0.145	P=0.416	P=0.467
COCH-ARM / FISHERS	P=0.525	P=0.096	P=0.387	P=0.387
MAX-ISO-POLY-3	P=0.356	P=0.085	P=0.297	P=0.330

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Heart
Mineralization**

LESION RATES

OVERALL (a)	3/50 (6%)	0/50 (0%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	3/45.39	0/46.91	2/45.05	0/47.17
POLY-3 PERCENT (g)	6.6%	0%	4.4%	0%
TERMINAL (d)	1/36 (3%)	0/40 (0%)	1/37 (3%)	0/41 (0%)
FIRST INCIDENCE	543	---	715	---

STATISTICAL TESTS

POLY 3	P=0.123N	P=0.113N	P=0.503N	P=0.112N
POLY 1.5	P=0.124N	P=0.116N	P=0.503N	P=0.115N
POLY 6	P=0.122N	P=0.110N	P=0.502N	P=0.108N
COCH-ARM / FISHERS	P=0.125N	P=0.121N	P=0.500N	P=0.121N
MAX-ISO-POLY-3	P=0.041N*	P=0.038N*	P=0.327N	P=0.038N*

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Heart
Thrombosis**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	0/44.58	0/46.91	2/45.55	0/47.17
POLY-3 PERCENT (g)	0%	0%	4.4%	0%
TERMINAL (d)	0/36 (0%)	0/40 (0%)	0/37 (0%)	0/41 (0%)
FIRST INCIDENCE	---	---	589	---

STATISTICAL TESTS

POLY 3	P=0.618	(e)	P=0.242	(e)
POLY 1.5	P=0.608	(e)	P=0.239	(e)
POLY 6	P=0.633	(e)	P=0.247	(e)
COCH-ARM / FISHERS	P=0.595	(e)	P=0.247	(e)
MAX-ISO-POLY-3	P=0.267	(e)	P=0.080	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Islets, Pancreatic
Hyperplasia**

LESION RATES

OVERALL (a)	0/50 (0%)	2/49 (4%)	1/49 (2%)	0/49 (0%)
POLY-3 RATE (b)	0/44.58	2/46.39	1/44.90	0/46.28
POLY-3 PERCENT (g)	0%	4.3%	2.2%	0%
TERMINAL (d)	0/36 (0%)	1/40 (3%)	0/37 (0%)	0/41 (0%)
FIRST INCIDENCE	---	660	589	---

STATISTICAL TESTS

POLY 3	P=0.442N	P=0.246	P=0.501	(e)
POLY 1.5	P=0.452N	P=0.240	P=0.498	(e)
POLY 6	P=0.426N	P=0.255	P=0.506	(e)
COCH-ARM / FISHERS	P=0.465N	P=0.242	P=0.495	(e)
MAX-ISO-POLY-3	P=0.341N	P=0.086	P=0.162	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Kidney
Infarct**

LESION RATES

OVERALL (a)	0/50 (0%)	0/49 (0%)	0/49 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/44.58	0/46.13	0/44.42	0/47.17
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/36 (0%)	0/40 (0%)	0/37 (0%)	0/41 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Kidney
Inflammation**

LESION RATES

OVERALL (a)	0/50 (0%)	0/49 (0%)	1/49 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/44.58	0/46.13	1/44.90	0/47.17
POLY-3 PERCENT (g)	0%	0%	2.2%	0%
TERMINAL (d)	0/36 (0%)	0/40 (0%)	0/37 (0%)	0/41 (0%)
FIRST INCIDENCE	---	---	589	---

STATISTICAL TESTS

POLY 3	P=0.711	(e)	P=0.501	(e)
POLY 1.5	P=0.703	(e)	P=0.498	(e)
POLY 6	P=0.721	(e)	P=0.506	(e)
COCH-ARM / FISHERS	P=0.694	(e)	P=0.495	(e)
MAX-ISO-POLY-3	P=0.400	(e)	P=0.162	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Kidney
Metaplasia Osseous**

LESION RATES

OVERALL (a)	3/50 (6%)	4/49 (8%)	0/49 (0%)	2/50 (4%)
POLY-3 RATE (b)	3/44.67	4/46.13	0/44.42	2/47.17
POLY-3 PERCENT (g)	6.7%	8.7%	0%	4.2%
TERMINAL (d)	2/36 (6%)	4/40 (10%)	0/37 (0%)	2/41 (5%)
FIRST INCIDENCE	708	731 (T)	---	731 (T)

STATISTICAL TESTS

POLY 3	P=0.250N	P=0.517	P=0.119N	P=0.475N
POLY 1.5	P=0.256N	P=0.505	P=0.121N	P=0.486N
POLY 6	P=0.242N	P=0.534	P=0.116N	P=0.460N
COCH-ARM / FISHERS	P=0.262N	P=0.489	P=0.125N	P=0.500N
MAX-ISO-POLY-3	P=0.187N	P=0.366	P=0.039N*	P=0.307N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Kidney
Mineralization**

LESION RATES

OVERALL (a)	0/50 (0%)	0/49 (0%)	0/49 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/44.58	0/46.13	0/44.42	0/47.17
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/36 (0%)	0/40 (0%)	0/37 (0%)	0/41 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Kidney
Nephropathy**

LESION RATES

OVERALL (a)	33/50 (66%)	37/49 (76%)	40/49 (82%)	39/50 (78%)
POLY-3 RATE (b)	33/46.77	37/48.39	40/47.26	39/48.70
POLY-3 PERCENT (g)	70.6%	76.5%	84.6%	80.1%
TERMINAL (d)	25/36 (69%)	30/40 (75%)	34/37 (92%)	33/41 (81%)
FIRST INCIDENCE	607	505	345	568

STATISTICAL TESTS

POLY 3	P=0.150	P=0.334	P=0.071	P=0.193
POLY 1.5	P=0.132	P=0.276	P=0.068	P=0.162
POLY 6	P=0.179	P=0.410	P=0.070	P=0.244
COCH-ARM / FISHERS	P=0.114	P=0.207	P=0.061	P=0.133
MAX-ISO-POLY-3	P=0.129	P=0.258	P=0.043*	P=0.138

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Kidney: Renal Tubule
Hyperplasia**

LESION RATES

OVERALL (a)	0/50 (0%)	0/49 (0%)	1/49 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/44.58	0/46.13	1/44.51	0/47.17
POLY-3 PERCENT (g)	0%	0%	2.3%	0%
TERMINAL (d)	0/36 (0%)	0/40 (0%)	0/37 (0%)	0/41 (0%)
FIRST INCIDENCE	---	---	708	---

STATISTICAL TESTS

POLY 3	P=0.711	(e)	P=0.500	(e)
POLY 1.5	P=0.704	(e)	P=0.497	(e)
POLY 6	P=0.721	(e)	P=0.504	(e)
COCH-ARM / FISHERS	P=0.694	(e)	P=0.495	(e)
MAX-ISO-POLY-3	P=0.399	(e)	P=0.159	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Larynx
Vacuolization Cytoplasmic**

LESION RATES

OVERALL (a)	0/50 (0%)	3/50 (6%)	2/50 (4%)	2/50 (4%)
POLY-3 RATE (b)	0/44.58	3/47.58	2/46.04	2/47.29
POLY-3 PERCENT (g)	0%	6.3%	4.3%	4.2%
TERMINAL (d)	0/36 (0%)	0/40 (0%)	0/37 (0%)	0/41 (0%)
FIRST INCIDENCE	---	625	345	703

STATISTICAL TESTS

POLY 3	P=0.354	P=0.131	P=0.244	P=0.251
POLY 1.5	P=0.341	P=0.126	P=0.241	P=0.245
POLY 6	P=0.374	P=0.139	P=0.249	P=0.260
COCH-ARM / FISHERS	P=0.324	P=0.121	P=0.247	P=0.247
MAX-ISO-POLY-3	P=0.182	P=0.048*	P=0.083	P=0.089

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Liver
Angiectasis**

LESION RATES

OVERALL (a)	0/50 (0%)	1/50 (2%)	1/50 (2%)	2/50 (4%)
POLY-3 RATE (b)	0/44.58	1/46.99	1/44.98	2/47.22
POLY-3 PERCENT (g)	0%	2.1%	2.2%	4.2%
TERMINAL (d)	0/36 (0%)	0/40 (0%)	1/37 (3%)	1/41 (2%)
FIRST INCIDENCE	---	709	731 (T)	719

STATISTICAL TESTS

POLY 3	P=0.165	P=0.511	P=0.502	P=0.250
POLY 1.5	P=0.160	P=0.506	P=0.500	P=0.244
POLY 6	P=0.173	P=0.517	P=0.504	P=0.259
COCH-ARM / FISHERS	P=0.153	P=0.500	P=0.500	P=0.247
MAX-ISO-POLY-3	P=0.142	P=0.172	P=0.161	P=0.089

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	CONTROL	Females		
		62.5 PPM	125 PPM	250 PPM

**Liver
Basophilic Focus**

LESION RATES

OVERALL (a)	2/50 (4%)	3/50 (6%)	2/50 (4%)	3/50 (6%)
POLY-3 RATE (b)	2/44.58	3/46.91	2/44.98	3/47.22
POLY-3 PERCENT (g)	4.5%	6.4%	4.5%	6.4%
TERMINAL (d)	2/36 (6%)	3/40 (8%)	2/37 (5%)	2/41 (5%)
FIRST INCIDENCE	731 (T)	731 (T)	731 (T)	719

STATISTICAL TESTS

POLY 3	P=0.480	P=0.523	P=0.691N	P=0.526
POLY 1.5	P=0.469	P=0.513	P=0.693N	P=0.514
POLY 6	P=0.496	P=0.537	P=0.686N	P=0.543
COCH-ARM / FISHERS	P=0.456	P=0.500	P=0.691N	P=0.500
MAX-ISO-POLY-3	P=0.556	P=0.348	P=0.496N	P=0.351

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

Liver
Clear Cell Focus

LESION RATES

OVERALL (a)	2/50 (4%)	0/50 (0%)	1/50 (2%)	2/50 (4%)
POLY-3 RATE (b)	2/44.58	0/46.91	1/44.98	2/47.17
POLY-3 PERCENT (g)	4.5%	0%	2.2%	4.2%
TERMINAL (d)	2/36 (6%)	0/40 (0%)	1/37 (3%)	2/41 (5%)
FIRST INCIDENCE	731 (T)	---	731 (T)	731 (T)

STATISTICAL TESTS

POLY 3	P=0.475	P=0.226N	P=0.497N	P=0.673N
POLY 1.5	P=0.472	P=0.231N	P=0.499N	P=0.682N
POLY 6	P=0.478	P=0.220N	P=0.492N	P=0.660N
COCH-ARM / FISHERS	P=0.469	P=0.247N	P=0.500N	P=0.691N
MAX-ISO-POLY-3	P=0.409N	P=0.076N	P=0.279N	P=0.477N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Liver
Eosinophilic Focus**

LESION RATES

OVERALL (a)	6/50 (12%)	7/50 (14%)	7/50 (14%)	5/50 (10%)
POLY-3 RATE (b)	6/45.18	7/46.91	7/44.98	5/47.17
POLY-3 PERCENT (g)	13.3%	14.9%	15.6%	10.6%
TERMINAL (d)	4/36 (11%)	7/40 (18%)	7/37 (19%)	5/41 (12%)
FIRST INCIDENCE	607	731 (T)	731 (T)	731 (T)

STATISTICAL TESTS

POLY 3	P=0.374N	P=0.529	P=0.497	P=0.470N
POLY 1.5	P=0.386N	P=0.517	P=0.496	P=0.483N
POLY 6	P=0.357N	P=0.544	P=0.499	P=0.452N
COCH-ARM / FISHERS	P=0.400N	P=0.500	P=0.500	P=0.500N
MAX-ISO-POLY-3	P=0.469N	P=0.411	P=0.378	P=0.348N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Liver
Fatty Change**

LESION RATES

OVERALL (a)	1/50 (2%)	1/50 (2%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	1/44.81	1/47.17	0/44.98	2/47.56
POLY-3 PERCENT (g)	2.2%	2.1%	0%	4.2%
TERMINAL (d)	0/36 (0%)	0/40 (0%)	0/37 (0%)	0/41 (0%)
FIRST INCIDENCE	669	660	---	655

STATISTICAL TESTS

POLY 3	P=0.376	P=0.749N	P=0.499N	P=0.521
POLY 1.5	P=0.372	P=0.754N	P=0.500N	P=0.511
POLY 6	P=0.382	P=0.742N	P=0.498N	P=0.534
COCH-ARM / FISHERS	P=0.366	P=0.753N	P=0.500N	P=0.500
MAX-ISO-POLY-3	P=0.308	P=0.485N	P=0.158N	P=0.303

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

Liver
Fatty Change Focal

LESION RATES

OVERALL (a)	2/50 (4%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	2/44.58	0/46.91	0/44.98	0/47.17
POLY-3 PERCENT (g)	4.5%	0%	0%	0%
TERMINAL (d)	2/36 (6%)	0/40 (0%)	0/37 (0%)	0/41 (0%)
FIRST INCIDENCE	731 (T)	---	---	---

STATISTICAL TESTS

POLY 3	P=0.119N	P=0.226N	P=0.235N	P=0.225N
POLY 1.5	P=0.117N	P=0.231N	P=0.237N	P=0.230N
POLY 6	P=0.123N	P=0.220N	P=0.232N	P=0.217N
COCH-ARM / FISHERS	P=0.115N	P=0.247N	P=0.247N	P=0.247N
MAX-ISO-POLY-3	P=0.032N*	P=0.076N	P=0.076N	P=0.076N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Liver
Mixed Cell Focus**

LESION RATES

OVERALL (a)	2/50 (4%)	3/50 (6%)	3/50 (6%)	0/50 (0%)
POLY-3 RATE (b)	2/44.58	3/47.08	3/45.62	0/47.17
POLY-3 PERCENT (g)	4.5%	6.4%	6.6%	0%
TERMINAL (d)	2/36 (6%)	2/40 (5%)	2/37 (5%)	0/41 (0%)
FIRST INCIDENCE	731 (T)	687	520	---

STATISTICAL TESTS

POLY 3	P=0.149N	P=0.525	P=0.511	P=0.225N
POLY 1.5	P=0.156N	P=0.514	P=0.505	P=0.230N
POLY 6	P=0.139N	P=0.540	P=0.519	P=0.217N
COCH-ARM / FISHERS	P=0.165N	P=0.500	P=0.500	P=0.247N
MAX-ISO-POLY-3	P=0.146N	P=0.349	P=0.335	P=0.076N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

Liver
Necrosis

LESION RATES

OVERALL (a)	1/50 (2%)	1/50 (2%)	2/50 (4%)	1/50 (2%)
POLY-3 RATE (b)	1/45.17	1/47.13	2/44.98	1/47.43
POLY-3 PERCENT (g)	2.2%	2.1%	4.5%	2.1%
TERMINAL (d)	0/36 (0%)	0/40 (0%)	2/37 (5%)	0/41 (0%)
FIRST INCIDENCE	543	673	731 (T)	663

STATISTICAL TESTS

POLY 3	P=0.607	P=0.751N	P=0.499	P=0.750N
POLY 1.5	P=0.600	P=0.755N	P=0.498	P=0.755N
POLY 6	P=0.619	P=0.745N	P=0.501	P=0.742N
COCH-ARM / FISHERS	P=0.591	P=0.753N	P=0.500	P=0.753N
MAX-ISO-POLY-3	P=0.593	P=0.487N	P=0.280	P=0.486N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Liver
Tension Lipidosis**

LESION RATES

OVERALL (a)	3/50 (6%)	10/50 (20%)	4/50 (8%)	1/50 (2%)
POLY-3 RATE (b)	3/44.88	10/46.94	4/45.34	1/47.17
POLY-3 PERCENT (g)	6.7%	21.3%	8.8%	2.1%
TERMINAL (d)	2/36 (6%)	9/40 (23%)	3/37 (8%)	1/41 (2%)
FIRST INCIDENCE	649	723	631	731 (T)

STATISTICAL TESTS

POLY 3	P=0.059N	P=0.042*	P=0.506	P=0.288N
POLY 1.5	P=0.065N	P=0.039*	P=0.502	P=0.296N
POLY 6	P=0.051N	P=0.046*	P=0.513	P=0.277N
COCH-ARM / FISHERS	P=0.078N	P=0.036*	P=0.500	P=0.309N
MAX-ISO-POLY-3	P=0.040N*	P=0.023*	P=0.353	P=0.148N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Lung
Hemorrhage**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/44.58	0/46.91	0/44.98	0/47.17
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/36 (0%)	0/40 (0%)	0/37 (0%)	0/41 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Lung
Inflammation Chronic**

LESION RATES

OVERALL (a)	0/50 (0%)	1/50 (2%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/44.58	1/46.91	0/44.98	0/47.17
POLY-3 PERCENT (g)	0%	2.1%	0%	0%
TERMINAL (d)	0/36 (0%)	1/40 (3%)	0/37 (0%)	0/41 (0%)
FIRST INCIDENCE	---	731 (T)	---	---

STATISTICAL TESTS

POLY 3	P=0.559N	P=0.510	(e)	(e)
POLY 1.5	P=0.563N	P=0.506	(e)	(e)
POLY 6	P=0.553N	P=0.516	(e)	(e)
COCH-ARM / FISHERS	P=0.567N	P=0.500	(e)	(e)
MAX-ISO-POLY-3	P=0.396N	P=0.171	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Lung: Alveolar Epithelium
Hyperplasia**

LESION RATES

OVERALL (a)	1/50 (2%)	1/50 (2%)	0/50 (0%)	3/50 (6%)
POLY-3 RATE (b)	1/44.58	1/46.91	0/44.98	3/47.17
POLY-3 PERCENT (g)	2.2%	2.1%	0%	6.4%
TERMINAL (d)	1/36 (3%)	1/40 (3%)	0/37 (0%)	3/41 (7%)
FIRST INCIDENCE	731 (T)	731 (T)	---	731 (T)

STATISTICAL TESTS

POLY 3	P=0.164	P=0.749N	P=0.498N	P=0.326
POLY 1.5	P=0.162	P=0.754N	P=0.500N	P=0.317
POLY 6	P=0.168	P=0.743N	P=0.496N	P=0.339
COCH-ARM / FISHERS	P=0.160	P=0.753N	P=0.500N	P=0.309
MAX-ISO-POLY-3	P=0.127	P=0.485N	P=0.158N	P=0.175

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Lung: Alveolus
Infiltration Cellular Histiocyte**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	4/50 (8%)	1/50 (2%)
POLY-3 RATE (b)	0/44.58	0/46.91	4/45.07	1/47.17
POLY-3 PERCENT (g)	0%	0%	8.9%	2.1%
TERMINAL (d)	0/36 (0%)	0/40 (0%)	3/37 (8%)	1/41 (2%)
FIRST INCIDENCE	---	---	708	731 (T)

STATISTICAL TESTS

POLY 3	P=0.265	(e)	P=0.061	P=0.511
POLY 1.5	P=0.255	(e)	P=0.061	P=0.506
POLY 6	P=0.280	(e)	P=0.063	P=0.518
COCH-ARM / FISHERS	P=0.245	(e)	P=0.059	P=0.500
MAX-ISO-POLY-3	P=0.090	(e)	P=0.020*	P=0.173

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Lung: Bronchiole
Hyperplasia**

LESION RATES

OVERALL (a)	1/50 (2%)	0/50 (0%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	1/44.58	0/46.91	0/44.98	1/47.17
POLY-3 PERCENT (g)	2.2%	0%	0%	2.1%
TERMINAL (d)	1/36 (3%)	0/40 (0%)	0/37 (0%)	1/41 (2%)
FIRST INCIDENCE	731 (T)	---	---	731 (T)

STATISTICAL TESTS

POLY 3	P=0.596	P=0.490N	P=0.498N	P=0.748N
POLY 1.5	P=0.595	P=0.494N	P=0.500N	P=0.753N
POLY 6	P=0.597	P=0.484N	P=0.496N	P=0.740N
COCH-ARM / FISHERS	P=0.595	P=0.500N	P=0.500N	P=0.753N
MAX-ISO-POLY-3	P=0.401N	P=0.158N	P=0.158N	P=0.484N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Lung: Bronchiole
Regeneration**

LESION RATES

OVERALL (a)	0/50 (0%)	45/50 (90%)	43/50 (86%)	49/50 (98%)
POLY-3 RATE (b)	0/44.58	45/49.46	43/48.63	49/50.00
POLY-3 PERCENT (g)	0%	91%	88.4%	98%
TERMINAL (d)	0/36 (0%)	39/40 (98%)	36/37 (97%)	40/41 (98%)
FIRST INCIDENCE	---	505	345	470

STATISTICAL TESTS

POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Lung: Bronchiole
Vacuolization Cytoplasmic**

LESION RATES

OVERALL (a)	0/50 (0%)	3/50 (6%)	4/50 (8%)	3/50 (6%)
POLY-3 RATE (b)	0/44.58	3/47.81	4/47.05	3/47.34
POLY-3 PERCENT (g)	0%	6.3%	8.5%	6.3%
TERMINAL (d)	0/36 (0%)	0/40 (0%)	0/37 (0%)	0/41 (0%)
FIRST INCIDENCE	---	583	345	703

STATISTICAL TESTS

POLY 3	P=0.184	P=0.132	P=0.067	P=0.130
POLY 1.5	P=0.174	P=0.126	P=0.065	P=0.125
POLY 6	P=0.200	P=0.140	P=0.072	P=0.138
COCH-ARM / FISHERS	P=0.162	P=0.121	P=0.059	P=0.121
MAX-ISO-POLY-3	P=0.101	P=0.049*	P=0.025*	P=0.047*

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Lymph Node, Mesenteric
Angiectasis**

LESION RATES

OVERALL (a)	2/48 (4%)	2/47 (4%)	0/47 (0%)	1/49 (2%)
POLY-3 RATE (b)	2/43.77	2/44.42	0/42.05	1/46.17
POLY-3 PERCENT (g)	4.6%	4.5%	0%	2.2%
TERMINAL (d)	2/36 (6%)	1/39 (3%)	0/35 (0%)	1/40 (3%)
FIRST INCIDENCE	731 (T)	678	---	731 (T)

STATISTICAL TESTS

POLY 3	P=0.289N	P=0.689N	P=0.246N	P=0.481N
POLY 1.5	P=0.290N	P=0.693	P=0.245N	P=0.487N
POLY 6	P=0.286N	P=0.679N	P=0.246N	P=0.473N
COCH-ARM / FISHERS	P=0.290N	P=0.684	P=0.253N	P=0.492N
MAX-ISO-POLY-3	P=0.272N	P=0.493N	P=0.083N	P=0.269N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Lymph Node: Iliac
Angiectasis**

LESION RATES

OVERALL (a)	2/6 (33%)	1/5 (20%)	0/3 (0%)	0/8 (0%)
POLY-3 RATE (b)	2/5.35	1/5.00	0/2.64	0/7.47
POLY-3 PERCENT (g)	37.4%	20%	0%	0%
TERMINAL (d)	1/3 (33%)	0/4 (0%)	0/2 (0%)	0/6 (0%)
FIRST INCIDENCE	649	687	---	---

STATISTICAL TESTS

POLY 3	P=0.074N	P=0.526N	P=0.393N	P=0.135N
POLY 1.5	P=0.075N	P=0.545N	P=0.393N	P=0.142N
POLY 6	P=0.073N	P=0.495N	P=0.394N	P=0.124N
COCH-ARM / FISHERS	P=0.075N	P=0.576N	P=0.417N	P=0.165N
MAX-ISO-POLY-3	P=0.069N	P=0.286N	P=0.169N	P=0.038N*

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Mesentery: Fat
Necrosis**

LESION RATES

OVERALL (a)	9/11 (82%)	9/9 (100%)	9/11 (82%)	12/13 (92%)
POLY-3 RATE (b)	9/11.00	9/9.00	9/10.64	12/12.89
POLY-3 PERCENT (g)	81.8%	100%	84.6%	93.1%
TERMINAL (d)	5/7 (71%)	8/8 (100%)	8/9 (89%)	11/11 (100%)
FIRST INCIDENCE	562	660	715	719

STATISTICAL TESTS

POLY 3	P=0.412	P=0.275	P=0.654	P=0.417
POLY 1.5	P=0.430	P=0.275	P=0.677	P=0.428
POLY 6	P=0.379	P=0.275	P=0.616	P=0.394
COCH-ARM / FISHERS	P=0.447	P=0.289	P=0.707N	P=0.435
MAX-ISO-POLY-3	P=0.304	P=0.100	P=0.433	P=0.211

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Nose
Inflammation**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	0/44.58	0/46.91	0/44.98	1/47.17
POLY-3 PERCENT (g)	0%	0%	0%	2.1%
TERMINAL (d)	0/36 (0%)	0/40 (0%)	0/37 (0%)	1/41 (2%)
FIRST INCIDENCE	---	---	---	731 (T)

STATISTICAL TESTS

POLY 3	P=0.204	(e)	(e)	P=0.511
POLY 1.5	P=0.202	(e)	(e)	P=0.506
POLY 6	P=0.207	(e)	(e)	P=0.518
COCH-ARM / FISHERS	P=0.198	(e)	(e)	P=0.500
MAX-ISO-POLY-3	P=0.143	(e)	(e)	P=0.173

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Nose
Polyp, Inflammatory**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/44.58	0/46.91	0/44.98	0/47.17
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/36 (0%)	0/40 (0%)	0/37 (0%)	0/41 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Nose: Olfactory Epithelium
Atrophy**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	6/50 (12%)
POLY-3 RATE (b)	0/44.58	0/46.91	0/44.98	6/47.91
POLY-3 PERCENT (g)	0%	0%	0%	12.5%
TERMINAL (d)	0/36 (0%)	0/40 (0%)	0/37 (0%)	5/41 (12%)
FIRST INCIDENCE	---	---	---	470

STATISTICAL TESTS

POLY 3	P<0.001**	(e)	(e)	P=0.020*
POLY 1.5	P<0.001**	(e)	(e)	P=0.018*
POLY 6	P<0.001**	(e)	(e)	P=0.022*
COCH-ARM / FISHERS	P<0.001**	(e)	(e)	P=0.013*
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	P=0.008**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Nose: Olfactory Epithelium
Metaplasia Respiratory**

LESION RATES

OVERALL (a)	0/50 (0%)	4/50 (8%)	5/50 (10%)	14/50 (28%)
POLY-3 RATE (b)	0/44.58	4/47.08	5/44.98	14/47.47
POLY-3 PERCENT (g)	0%	8.5%	11.1%	29.5%
TERMINAL (d)	0/36 (0%)	3/40 (8%)	5/37 (14%)	13/41 (32%)
FIRST INCIDENCE	---	687	731 (T)	649

STATISTICAL TESTS

POLY 3	P<0.001**	P=0.068	P=0.031*	P<0.001**
POLY 1.5	P<0.001**	P=0.064	P=0.031*	P<0.001**
POLY 6	P<0.001**	P=0.072	P=0.032*	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.059	P=0.028*	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P=0.025*	P=0.010**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Nose: Respiratory Epithelium
Hyperplasia**

LESION RATES

OVERALL (a)	11/50 (22%)	25/50 (50%)	28/50 (56%)	27/50 (54%)
POLY-3 RATE (b)	11/44.99	25/47.82	28/49.01	27/48.91
POLY-3 PERCENT (g)	24.5%	52.3%	57.1%	55.2%
TERMINAL (d)	9/36 (25%)	20/40 (50%)	17/37 (46%)	22/41 (54%)
FIRST INCIDENCE	669	625	520	554

STATISTICAL TESTS

POLY 3	P=0.007**	P=0.004**	P<0.001**	P=0.002**
POLY 1.5	P=0.004**	P=0.003**	P<0.001**	P<0.001**
POLY 6	P=0.013*	P=0.006**	P=0.002**	P=0.003**
COCH-ARM / FISHERS	P=0.003**	P=0.003**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P=0.002**	P=0.003**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Nose: Respiratory Epithelium
Vacuolization Cytoplasmic**

LESION RATES

OVERALL (a)	0/50 (0%)	3/50 (6%)	5/50 (10%)	8/50 (16%)
POLY-3 RATE (b)	0/44.58	3/47.81	5/47.70	8/47.23
POLY-3 PERCENT (g)	0%	6.3%	10.5%	16.9%
TERMINAL (d)	0/36 (0%)	0/40 (0%)	0/37 (0%)	6/41 (15%)
FIRST INCIDENCE	---	583	345	719

STATISTICAL TESTS

POLY 3	P=0.003**	P=0.132	P=0.037*	P=0.005**
POLY 1.5	P=0.002**	P=0.126	P=0.034*	P=0.004**
POLY 6	P=0.003**	P=0.140	P=0.040*	P=0.006**
COCH-ARM / FISHERS	P=0.002**	P=0.121	P=0.028*	P=0.003**
MAX-ISO-POLY-3	P=0.004**	P=0.049*	P=0.014*	P=0.002**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Ovary
Angiectasis**

LESION RATES

OVERALL (a)	1/50 (2%)	2/50 (4%)	0/50 (0%)	2/49 (4%)
POLY-3 RATE (b)	1/44.58	2/46.91	0/44.98	2/46.17
POLY-3 PERCENT (g)	2.2%	4.3%	0%	4.3%
TERMINAL (d)	1/36 (3%)	2/40 (5%)	0/37 (0%)	2/40 (5%)
FIRST INCIDENCE	731 (T)	731 (T)	---	731 (T)

STATISTICAL TESTS

POLY 3	P=0.477	P=0.518	P=0.498N	P=0.512
POLY 1.5	P=0.470	P=0.510	P=0.500N	P=0.504
POLY 6	P=0.487	P=0.528	P=0.496N	P=0.525
COCH-ARM / FISHERS	P=0.462	P=0.500	P=0.500N	P=0.492
MAX-ISO-POLY-3	P=0.438	P=0.300	P=0.158N	P=0.295

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Ovary
Cyst**

LESION RATES

OVERALL (a)	12/50 (24%)	8/50 (16%)	12/50 (24%)	2/49 (4%)
POLY-3 RATE (b)	12/46.07	8/47.30	12/44.98	2/46.17
POLY-3 PERCENT (g)	26.1%	16.9%	26.7%	4.3%
TERMINAL (d)	9/36 (25%)	6/40 (15%)	12/37 (32%)	2/40 (5%)
FIRST INCIDENCE	543	673	731 (T)	731 (T)

STATISTICAL TESTS

POLY 3	P=0.008N**	P=0.205N	P=0.567	P=0.003N**
POLY 1.5	P=0.009N**	P=0.215N	P=0.575	P=0.004N**
POLY 6	P=0.007N**	P=0.191N	P=0.561	P=0.003N**
COCH-ARM / FISHERS	P=0.010N**	P=0.227N	P=0.592N	P=0.004N**
MAX-ISO-POLY-3	P=0.005N**	P=0.144N	P=0.472	P<0.001N**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Ovary
Thrombosis**

LESION RATES

OVERALL (a)	2/50 (4%)	2/50 (4%)	0/50 (0%)	1/49 (2%)
POLY-3 RATE (b)	2/44.58	2/46.91	0/44.98	1/46.17
POLY-3 PERCENT (g)	4.5%	4.3%	0%	2.2%
TERMINAL (d)	2/36 (6%)	2/40 (5%)	0/37 (0%)	1/40 (3%)
FIRST INCIDENCE	731 (T)	731 (T)	---	731 (T)

STATISTICAL TESTS

POLY 3	P=0.297N	P=0.675N	P=0.235N	P=0.488N
POLY 1.5	P=0.299N	P=0.683N	P=0.237N	P=0.496N
POLY 6	P=0.292N	P=0.665N	P=0.232N	P=0.475N
COCH-ARM / FISHERS	P=0.301N	P=0.691N	P=0.247N	P=0.508N
MAX-ISO-POLY-3	P=0.271N	P=0.479N	P=0.076N	P=0.275N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Pancreas
Atrophy**

LESION RATES

OVERALL (a)	7/50 (14%)	4/49 (8%)	5/50 (10%)	2/50 (4%)
POLY-3 RATE (b)	7/44.81	4/46.13	5/45.23	2/47.17
POLY-3 PERCENT (g)	15.6%	8.7%	11.1%	4.2%
TERMINAL (d)	6/36 (17%)	4/40 (10%)	4/37 (11%)	2/41 (5%)
FIRST INCIDENCE	669	731 (T)	663	731 (T)

STATISTICAL TESTS

POLY 3	P=0.069N	P=0.244N	P=0.372N	P=0.067N
POLY 1.5	P=0.072N	P=0.257N	P=0.378N	P=0.072N
POLY 6	P=0.064N	P=0.228N	P=0.362N	P=0.060N
COCH-ARM / FISHERS	P=0.076N	P=0.274N	P=0.380N	P=0.080N
MAX-ISO-POLY-3	P=0.057N	P=0.160N	P=0.264N	P=0.035N*

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Pancreas
Basophilic Focus**

LESION RATES

OVERALL (a)	1/50 (2%)	2/49 (4%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/44.58	2/46.71	0/44.98	0/47.17
POLY-3 PERCENT (g)	2.2%	4.3%	0%	0%
TERMINAL (d)	1/36 (3%)	1/40 (3%)	0/37 (0%)	0/41 (0%)
FIRST INCIDENCE	731 (T)	547	---	---

STATISTICAL TESTS

POLY 3	P=0.179N	P=0.516	P=0.498N	P=0.489N
POLY 1.5	P=0.183N	P=0.506	P=0.500N	P=0.494N
POLY 6	P=0.174N	P=0.530	P=0.496N	P=0.482N
COCH-ARM / FISHERS	P=0.187N	P=0.492	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.182N	P=0.299	P=0.158N	P=0.158N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Pituitary Gland: Pars Distalis
Angiectasis**

LESION RATES

OVERALL (a)	1/46 (2%)	1/49 (2%)	2/47 (4%)	0/48 (0%)
POLY-3 RATE (b)	1/40.98	1/45.91	2/42.93	0/45.98
POLY-3 PERCENT (g)	2.4%	2.2%	4.7%	0%
TERMINAL (d)	1/34 (3%)	1/39 (3%)	1/35 (3%)	0/41 (0%)
FIRST INCIDENCE	731 (T)	731 (T)	589	---

STATISTICAL TESTS

POLY 3	P=0.340N	P=0.735N	P=0.516	P=0.477N
POLY 1.5	P=0.349N	P=0.740N	P=0.512	P=0.483N
POLY 6	P=0.328N	P=0.729N	P=0.523	P=0.468N
COCH-ARM / FISHERS	P=0.359N	P=0.737N	P=0.508	P=0.489N
MAX-ISO-POLY-3	P=0.291N	P=0.468N	P=0.297	P=0.156N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Pituitary Gland: Pars Distalis
Hyperplasia**

LESION RATES

OVERALL (a)	15/46 (33%)	14/49 (29%)	11/47 (23%)	15/48 (31%)
POLY-3 RATE (b)	15/41.69	14/46.33	11/42.46	15/45.98
POLY-3 PERCENT (g)	36%	30.2%	25.9%	32.6%
TERMINAL (d)	14/34 (41%)	12/39 (31%)	11/35 (31%)	15/41 (37%)
FIRST INCIDENCE	481	673	731 (T)	731 (T)

STATISTICAL TESTS

POLY 3	P=0.455N	P=0.364N	P=0.221N	P=0.458N
POLY 1.5	P=0.477N	P=0.389N	P=0.226N	P=0.492N
POLY 6	P=0.422N	P=0.329N	P=0.211N	P=0.408N
COCH-ARM / FISHERS	P=0.501N	P=0.419N	P=0.224N	P=0.532N
MAX-ISO-POLY-3	P=0.420N	P=0.290N	P=0.158N	P=0.374N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Pituitary Gland: Pars Intermedia
Hyperplasia**

LESION RATES

OVERALL (a)	0/46 (0%)	1/49 (2%)	2/47 (4%)	0/48 (0%)
POLY-3 RATE (b)	0/40.98	1/45.91	2/42.46	0/45.98
POLY-3 PERCENT (g)	0%	2.2%	4.7%	0%
TERMINAL (d)	0/34 (0%)	1/39 (3%)	2/35 (6%)	0/41 (0%)
FIRST INCIDENCE	---	731 (T)	731 (T)	---

STATISTICAL TESTS

POLY 3	P=0.584N	P=0.523	P=0.245	(e)
POLY 1.5	P=0.595N	P=0.518	P=0.243	(e)
POLY 6	P=0.567N	P=0.528	P=0.248	(e)
COCH-ARM / FISHERS	P=0.610N	P=0.516	P=0.253	(e)
MAX-ISO-POLY-3	P=0.345N	P=0.182	P=0.082	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Skin
Inflammation Chronic**

LESION RATES

OVERALL (a)	0/50 (0%)	4/50 (8%)	2/50 (4%)	1/50 (2%)
POLY-3 RATE (b)	0/44.58	4/47.08	2/45.62	1/47.17
POLY-3 PERCENT (g)	0%	8.5%	4.4%	2.1%
TERMINAL (d)	0/36 (0%)	3/40 (8%)	1/37 (3%)	1/41 (2%)
FIRST INCIDENCE	---	687	520	731 (T)

STATISTICAL TESTS

POLY 3	P=0.545N	P=0.068	P=0.242	P=0.511
POLY 1.5	P=0.560N	P=0.064	P=0.240	P=0.506
POLY 6	P=0.525N	P=0.072	P=0.246	P=0.518
COCH-ARM / FISHERS	P=0.577N	P=0.059	P=0.247	P=0.500
MAX-ISO-POLY-3	P=0.177	P=0.025*	P=0.081	P=0.173

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

Spleen Atrophy

LESION RATES

OVERALL (a)	4/50 (8%)	1/49 (2%)	2/50 (4%)	5/50 (10%)
POLY-3 RATE (b)	4/46.31	1/46.33	2/45.33	5/48.12
POLY-3 PERCENT (g)	8.6%	2.2%	4.4%	10.4%
TERMINAL (d)	1/36 (3%)	0/40 (0%)	0/37 (0%)	1/41 (2%)
FIRST INCIDENCE	540	678	663	568

STATISTICAL TESTS

POLY 3	P=0.284	P=0.179N	P=0.347N	P=0.524
POLY 1.5	P=0.280	P=0.182N	P=0.345N	P=0.513
POLY 6	P=0.290	P=0.173N	P=0.347N	P=0.542
COCH-ARM / FISHERS	P=0.276	P=0.187N	P=0.339N	P=0.500
MAX-ISO-POLY-3	P=0.242	P=0.085N	P=0.211N	P=0.387

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Spleen
Congestion**

LESION RATES

OVERALL (a)	0/50 (0%)	0/49 (0%)	1/50 (2%)	2/50 (4%)
POLY-3 RATE (b)	0/44.58	0/46.13	1/45.46	2/47.75
POLY-3 PERCENT (g)	0%	0%	2.2%	4.2%
TERMINAL (d)	0/36 (0%)	0/40 (0%)	0/37 (0%)	0/41 (0%)
FIRST INCIDENCE	---	---	589	649

STATISTICAL TESTS

POLY 3	P=0.077	(e)	P=0.504	P=0.253
POLY 1.5	P=0.074	(e)	P=0.502	P=0.246
POLY 6	P=0.081	(e)	P=0.508	P=0.264
COCH-ARM / FISHERS	P=0.071	(e)	P=0.500	P=0.247
MAX-ISO-POLY-3	P=0.098	(e)	P=0.163	P=0.091

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	CONTROL	Females		
		62.5 PPM	125 PPM	250 PPM

**Spleen
Hematopoietic Cell Proliferation**

LESION RATES

OVERALL (a)	13/50 (26%)	10/49 (20%)	13/50 (26%)	16/50 (32%)
POLY-3 RATE (b)	13/47.05	10/47.41	13/47.47	16/48.40
POLY-3 PERCENT (g)	27.6%	21.1%	27.4%	33.1%
TERMINAL (d)	8/36 (22%)	6/40 (15%)	7/37 (19%)	11/41 (27%)
FIRST INCIDENCE	540	505	520	568

STATISTICAL TESTS

POLY 3	P=0.212	P=0.309N	P=0.581N	P=0.362
POLY 1.5	P=0.205	P=0.322N	P=0.588N	P=0.346
POLY 6	P=0.227	P=0.291N	P=0.566N	P=0.390
COCH-ARM / FISHERS	P=0.198	P=0.337N	P=0.590N	P=0.330
MAX-ISO-POLY-3	P=0.280	P=0.233N	P=0.489N	P=0.286

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Spleen
Hyperplasia**

LESION RATES

OVERALL (a)	2/50 (4%)	0/49 (0%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	2/44.58	0/46.13	0/44.98	1/47.17
POLY-3 PERCENT (g)	4.5%	0%	0%	2.1%
TERMINAL (d)	2/36 (6%)	0/40 (0%)	0/37 (0%)	1/41 (2%)
FIRST INCIDENCE	731 (T)	---	---	731 (T)

STATISTICAL TESTS

POLY 3	P=0.469N	P=0.230N	P=0.235N	P=0.480N
POLY 1.5	P=0.465N	P=0.235N	P=0.237N	P=0.489N
POLY 6	P=0.475N	P=0.222N	P=0.232N	P=0.468N
COCH-ARM / FISHERS	P=0.459N	P=0.253N	P=0.247N	P=0.500N
MAX-ISO-POLY-3	P=0.133N	P=0.077N	P=0.076N	P=0.270N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	CONTROL	Females		
		62.5 PPM	125 PPM	250 PPM

**Spleen
Hyperplasia Lymphoid**

LESION RATES

OVERALL (a)	7/50 (14%)	7/49 (14%)	5/50 (10%)	3/50 (6%)
POLY-3 RATE (b)	7/45.29	7/46.13	5/44.98	3/47.17
POLY-3 PERCENT (g)	15.5%	15.2%	11.1%	6.4%
TERMINAL (d)	6/36 (17%)	7/40 (18%)	5/37 (14%)	3/41 (7%)
FIRST INCIDENCE	481	731 (T)	731 (T)	731 (T)

STATISTICAL TESTS

POLY 3	P=0.086N	P=0.599N	P=0.384N	P=0.141N
POLY 1.5	P=0.091N	P=0.613N	P=0.385N	P=0.149N
POLY 6	P=0.078N	P=0.579N	P=0.378N	P=0.129N
COCH-ARM / FISHERS	P=0.095N	P=0.597	P=0.380N	P=0.159N
MAX-ISO-POLY-3	P=0.135N	P=0.485N	P=0.274N	P=0.083N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Spleen
Necrosis Lymphoid**

LESION RATES

OVERALL (a)	0/50 (0%)	1/49 (2%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/44.58	1/46.33	1/45.46	0/47.17
POLY-3 PERCENT (g)	0%	2.2%	2.2%	0%
TERMINAL (d)	0/36 (0%)	0/40 (0%)	0/37 (0%)	0/41 (0%)
FIRST INCIDENCE	---	678	589	---

STATISTICAL TESTS

POLY 3	P=0.577N	P=0.508	P=0.504	(e)
POLY 1.5	P=0.584N	P=0.503	P=0.502	(e)
POLY 6	P=0.567N	P=0.515	P=0.508	(e)
COCH-ARM / FISHERS	P=0.593N	P=0.495	P=0.500	(e)
MAX-ISO-POLY-3	P=0.414N	P=0.169	P=0.163	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Spleen
Pigmentation Hemosiderin**

LESION RATES

OVERALL (a)	1/50 (2%)	2/49 (4%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/44.67	2/46.56	0/44.98	0/47.17
POLY-3 PERCENT (g)	2.2%	4.3%	0%	0%
TERMINAL (d)	0/36 (0%)	0/40 (0%)	0/37 (0%)	0/41 (0%)
FIRST INCIDENCE	708	660	---	---

STATISTICAL TESTS

POLY 3	P=0.180N	P=0.514	P=0.499N	P=0.489N
POLY 1.5	P=0.183N	P=0.505	P=0.500N	P=0.494N
POLY 6	P=0.175N	P=0.528	P=0.496N	P=0.482N
COCH-ARM / FISHERS	P=0.187N	P=0.492	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.181N	P=0.297	P=0.158N	P=0.158N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Stomach, Forestomach
Hyperplasia**

LESION RATES

OVERALL (a)	3/50 (6%)	2/50 (4%)	2/49 (4%)	1/50 (2%)
POLY-3 RATE (b)	3/45.33	2/47.17	2/44.21	1/47.17
POLY-3 PERCENT (g)	6.6%	4.2%	4.5%	2.1%
TERMINAL (d)	0/36 (0%)	1/40 (3%)	1/37 (3%)	1/41 (2%)
FIRST INCIDENCE	649	660	708	731 (T)

STATISTICAL TESTS

POLY 3	P=0.228N	P=0.482N	P=0.511N	P=0.291N
POLY 1.5	P=0.231N	P=0.489N	P=0.512N	P=0.297N
POLY 6	P=0.224N	P=0.473N	P=0.510N	P=0.284N
COCH-ARM / FISHERS	P=0.233N	P=0.500N	P=0.510N	P=0.309N
MAX-ISO-POLY-3	P=0.243N	P=0.311N	P=0.335N	P=0.149N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Stomach, Forestomach
Inflammation**

LESION RATES

OVERALL (a)	1/50 (2%)	0/50 (0%)	0/49 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/44.88	0/46.91	0/44.12	0/47.17
POLY-3 PERCENT (g)	2.2%	0%	0%	0%
TERMINAL (d)	0/36 (0%)	0/40 (0%)	0/37 (0%)	0/41 (0%)
FIRST INCIDENCE	649	---	---	---

STATISTICAL TESTS

POLY 3	P=0.316N	P=0.491N	P=0.503N	P=0.490N
POLY 1.5	P=0.312N	P=0.495N	P=0.504N	P=0.494N
POLY 6	P=0.321N	P=0.486N	P=0.502N	P=0.484N
COCH-ARM / FISHERS	P=0.306N	P=0.500N	P=0.505N	P=0.500N
MAX-ISO-POLY-3	P=0.124N	P=0.158N	P=0.162N	P=0.158N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Stomach, Forestomach
Ulcer**

LESION RATES

OVERALL (a)	2/50 (4%)	2/50 (4%)	0/49 (0%)	2/50 (4%)
POLY-3 RATE (b)	2/45.03	2/47.34	0/44.12	2/47.54
POLY-3 PERCENT (g)	4.4%	4.2%	0%	4.2%
TERMINAL (d)	0/36 (0%)	0/40 (0%)	0/37 (0%)	0/41 (0%)
FIRST INCIDENCE	669	660	---	663

STATISTICAL TESTS

POLY 3	P=0.551N	P=0.676N	P=0.242N	P=0.674N
POLY 1.5	P=0.554N	P=0.683N	P=0.242N	P=0.683N
POLY 6	P=0.547N	P=0.666N	P=0.240N	P=0.662N
COCH-ARM / FISHERS	P=0.556N	P=0.691N	P=0.253N	P=0.691N
MAX-ISO-POLY-3	P=0.445N	P=0.479N	P=0.079N	P=0.477N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Stomach, Glandular
Mineralization**

LESION RATES

OVERALL (a)	0/50 (0%)	0/49 (0%)	1/48 (2%)	1/50 (2%)
POLY-3 RATE (b)	0/44.58	0/46.13	1/43.56	1/47.18
POLY-3 PERCENT (g)	0%	0%	2.3%	2.1%
TERMINAL (d)	0/36 (0%)	0/40 (0%)	1/37 (3%)	0/41 (0%)
FIRST INCIDENCE	---	---	731 (T)	730

STATISTICAL TESTS

POLY 3	P=0.250	(e)	P=0.495	P=0.511
POLY 1.5	P=0.245	(e)	P=0.493	P=0.506
POLY 6	P=0.257	(e)	P=0.499	P=0.518
COCH-ARM / FISHERS	P=0.237	(e)	P=0.490	P=0.500
MAX-ISO-POLY-3	P=0.265	(e)	P=0.156	P=0.173

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Thymus
Atrophy**

LESION RATES

OVERALL (a)	14/49 (29%)	13/45 (29%)	17/45 (38%)	16/45 (36%)
POLY-3 RATE (b)	14/47.41	13/43.89	17/42.09	16/44.04
POLY-3 PERCENT (g)	29.5%	29.6%	40.4%	36.3%
TERMINAL (d)	4/35 (11%)	9/38 (24%)	12/34 (35%)	12/37 (32%)
FIRST INCIDENCE	540	505	520	470

STATISTICAL TESTS

POLY 3	P=0.225	P=0.586	P=0.196	P=0.320
POLY 1.5	P=0.224	P=0.582	P=0.209	P=0.316
POLY 6	P=0.226	P=0.589N	P=0.184	P=0.324
COCH-ARM / FISHERS	P=0.220	P=0.576	P=0.233	P=0.307
MAX-ISO-POLY-3	P=0.307	P=0.496	P=0.149	P=0.249

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Thymus
Cyst**

LESION RATES

OVERALL (a)	5/49 (10%)	7/45 (16%)	6/45 (13%)	9/45 (20%)
POLY-3 RATE (b)	5/44.60	7/42.63	6/40.39	9/43.74
POLY-3 PERCENT (g)	11.2%	16.4%	14.9%	20.6%
TERMINAL (d)	3/35 (9%)	7/38 (18%)	5/34 (15%)	6/37 (16%)
FIRST INCIDENCE	540	731 (T)	663	470

STATISTICAL TESTS

POLY 3	P=0.164	P=0.347	P=0.430	P=0.180
POLY 1.5	P=0.153	P=0.335	P=0.432	P=0.166
POLY 6	P=0.182	P=0.365	P=0.433	P=0.201
COCH-ARM / FISHERS	P=0.138	P=0.320	P=0.439	P=0.149
MAX-ISO-POLY-3	P=0.184	P=0.242	P=0.314	P=0.116

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Thymus
Necrosis Lymphoid**

LESION RATES

OVERALL (a)	0/49 (0%)	2/45 (4%)	4/45 (9%)	0/45 (0%)
POLY-3 RATE (b)	0/43.58	2/42.87	4/40.99	0/42.43
POLY-3 PERCENT (g)	0%	4.7%	9.8%	0%
TERMINAL (d)	0/35 (0%)	0/38 (0%)	2/34 (6%)	0/37 (0%)
FIRST INCIDENCE	---	678	537	---

STATISTICAL TESTS

POLY 3	P=0.548N	P=0.233	P=0.052	(e)
POLY 1.5	P=0.563N	P=0.227	P=0.051	(e)
POLY 6	P=0.527N	P=0.243	P=0.055	(e)
COCH-ARM / FISHERS	P=0.581N	P=0.226	P=0.049*	(e)
MAX-ISO-POLY-3	P=0.182	P=0.077	P=0.017*	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Thymus: Medulla
Hyperplasia Lymphoid**

LESION RATES

OVERALL (a)	25/49 (51%)	29/45 (64%)	30/45 (67%)	26/45 (58%)
POLY-3 RATE (b)	25/45.77	29/43.54	30/42.05	26/44.61
POLY-3 PERCENT (g)	54.6%	66.6%	71.3%	58.3%
TERMINAL (d)	20/35 (57%)	26/38 (68%)	26/34 (77%)	21/37 (57%)
FIRST INCIDENCE	481	505	520	470

STATISTICAL TESTS

POLY 3	P=0.488	P=0.168	P=0.074	P=0.444
POLY 1.5	P=0.428	P=0.152	P=0.078	P=0.392
POLY 6	P=0.521N	P=0.196	P=0.074	P=0.515
COCH-ARM / FISHERS	P=0.355	P=0.134	P=0.092	P=0.327
MAX-ISO-POLY-3	P=0.232	P=0.120	P=0.050*	P=0.362

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Tooth
Dysplasia**

LESION RATES

OVERALL (a)	0/0 (0%)	1/1 (100%)	0/0 (0%)	0/0 (0%)
POLY-3 RATE (b)	0/0.00	1/1.00	0/0.00	0/0.00
POLY-3 PERCENT (g)	0%	100%	0%	0%
TERMINAL (d)	0/0 (0%)	1/1 (100%)	0/0 (0%)	0/0 (0%)
FIRST INCIDENCE	---	731 (T)	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Trachea
Vacuolization Cytoplasmic**

LESION RATES

OVERALL (a)	0/50 (0%)	8/49 (16%)	7/50 (14%)	4/50 (8%)
POLY-3 RATE (b)	0/44.58	8/47.49	7/48.07	4/47.29
POLY-3 PERCENT (g)	0%	16.9%	14.6%	8.5%
TERMINAL (d)	0/36 (0%)	3/40 (8%)	0/37 (0%)	2/41 (5%)
FIRST INCIDENCE	---	583	345	703

STATISTICAL TESTS

POLY 3	P=0.322	P=0.005**	P=0.010**	P=0.068
POLY 1.5	P=0.299	P=0.004**	P=0.009**	P=0.065
POLY 6	P=0.355	P=0.006**	P=0.012*	P=0.074
COCH-ARM / FISHERS	P=0.275	P=0.003**	P=0.006**	P=0.059
MAX-ISO-POLY-3	P=0.030*	P=0.002**	P=0.004**	P=0.026*

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Urinary Bladder: Artery
Inflammation Chronic**

LESION RATES

OVERALL (a)	0/50 (0%)	0/49 (0%)	0/48 (0%)	2/50 (4%)
POLY-3 RATE (b)	0/44.58	0/46.13	0/43.56	2/47.79
POLY-3 PERCENT (g)	0%	0%	0%	4.2%
TERMINAL (d)	0/36 (0%)	0/40 (0%)	0/37 (0%)	0/41 (0%)
FIRST INCIDENCE	---	---	---	554

STATISTICAL TESTS

POLY 3	P=0.049*	(e)	(e)	P=0.253
POLY 1.5	P=0.048*	(e)	(e)	P=0.246
POLY 6	P=0.050*	(e)	(e)	P=0.263
COCH-ARM / FISHERS	P=0.048*	(e)	(e)	P=0.247
MAX-ISO-POLY-3	P=0.047*	(e)	(e)	P=0.091

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Uterus
Angiectasis**

LESION RATES

OVERALL (a)	2/50 (4%)	3/50 (6%)	6/50 (12%)	3/50 (6%)
POLY-3 RATE (b)	2/44.58	3/47.13	6/45.23	3/47.17
POLY-3 PERCENT (g)	4.5%	6.4%	13.3%	6.4%
TERMINAL (d)	2/36 (6%)	2/40 (5%)	5/37 (14%)	3/41 (7%)
FIRST INCIDENCE	731 (T)	673	663	731 (T)

STATISTICAL TESTS

POLY 3	P=0.422	P=0.525	P=0.137	P=0.526
POLY 1.5	P=0.407	P=0.514	P=0.135	P=0.514
POLY 6	P=0.443	P=0.540	P=0.142	P=0.542
COCH-ARM / FISHERS	P=0.389	P=0.500	P=0.134	P=0.500
MAX-ISO-POLY-3	P=0.289	P=0.350	P=0.073	P=0.350

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Uterus
Thrombosis**

LESION RATES

OVERALL (a)	1/50 (2%)	1/50 (2%)	2/50 (4%)	1/50 (2%)
POLY-3 RATE (b)	1/44.81	1/46.91	2/45.23	1/47.17
POLY-3 PERCENT (g)	2.2%	2.1%	4.4%	2.1%
TERMINAL (d)	0/36 (0%)	1/40 (3%)	1/37 (3%)	1/41 (2%)
FIRST INCIDENCE	669	731 (T)	663	731 (T)

STATISTICAL TESTS

POLY 3	P=0.608	P=0.750N	P=0.503	P=0.749N
POLY 1.5	P=0.600	P=0.755N	P=0.501	P=0.754N
POLY 6	P=0.619	P=0.745N	P=0.508	P=0.742N
COCH-ARM / FISHERS	P=0.591	P=0.753N	P=0.500	P=0.753N
MAX-ISO-POLY-3	P=0.596	P=0.487N	P=0.284	P=0.485N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	62.5 PPM	125 PPM	250 PPM

**Uterus: Endometrium
Hyperplasia Cystic**

LESION RATES

OVERALL (a)	39/50 (78%)	43/50 (86%)	43/50 (86%)	41/50 (82%)
POLY-3 RATE (b)	39/45.61	43/48.81	43/46.95	41/48.15
POLY-3 PERCENT (g)	85.5%	88.1%	91.6%	85.1%
TERMINAL (d)	34/36 (94%)	36/40 (90%)	37/37 (100%)	36/41 (88%)
FIRST INCIDENCE	646	547	520	554

STATISTICAL TESTS

POLY 3	P=0.513N	P=0.470	P=0.241	P=0.605N
POLY 1.5	P=0.526	P=0.336	P=0.219	P=0.528
POLY 6	P=0.396N	P=0.605N	P=0.296	P=0.453N
COCH-ARM / FISHERS	P=0.424	P=0.218	P=0.218	P=0.402
MAX-ISO-POLY-3	P=0.487N	P=0.345	P=0.142	P=0.478N

LEGEND

- (a) Number of tumor-bearing animals/number of animals examined at site.
 - (b) Number of tumor-bearing animals/Poly-3 number
 - (d) Observed incidence at terminal kill.
 - (f) Beneath the control incidence are the P-values associated with the trend test. Beneath the dosed group incidence are the P-values corresponding to pairwise comparisons between the controls and that dosed group. The life table analysis regards tumors in animals dying prior to terminal kill as being (directly or indirectly) the cause of death.
 - (e) Value of Statistic cannot be computed.
 - (g) Poly-3 adjusted lifetime tumor incidence.
 - (I) Interim sacrifice
 - (T) Terminal sacrifice
 - # Tumor rates based on numbers of animals necropsied.
 - * To the right of any statistical result, indicates significance at ($P \leq 0.05$).
 - ** To the right of any statistical result, indicates significance at ($P \leq 0.01$).
 - N Indicates a negative trend for all tests
- Logistic regression is an alternative method for analyzing the incidence of non-fatal tumors.
The Cochran-Armitage and Fishers exact tests compare directly the overall incidence rates.

*** END OF REPORT ***